INFERRING THE COVID-19 IFR WITH A SIMPLE BAYESIAN EVIDENCE SYNTHESIS OF SEROPREVALENCE STUDY DATA AND IMPRECISE MORTALITY DATA

Harlan Campbell

Department of Statistics, University of British Columbia Vancouver, British Columbia, Canada harlan.campbell@stat.ubc.ca ORCID ID: 0000-0002-0959-1594

Paul Gustafson

Department of Statistics, University of British Columbia Vancouver, British Columbia, Canada ORCID ID: 0000-0002-2375-5006

August 16, 2021

Acknowledgments - *This work was supported by the European Union's Horizon 2020 research and innovation programme under ReCoDID grant agreement No 825746 () and by the Canadian Institutes of Health Research, Institute of Genetics (CIHR-IG) under Grant Agreement No 01886- 000. We wish to thank Andrew Levin, Thomas Debray, Valentijn de Jong, and Thomas Jaenisch for their valuable feedback with the analysis and the writing of this manuscript. We also wish to thank Ariel Karlinsky, Nana Owusu-Boaitey, Lauren Maxwell, and Sayali Arvind Chavan for help with data collection. Finally, thank you to the many fellow researchers who helped with information about various data including, amongst others, Maurizio Napolitano, Shiwani Mahajan, Miguel Quartin, Stefano Lombardo, and Timon Gaertner.*

ABSTRACT - Estimating the COVID-19 infection fatality rate (IFR) has proven to be particularly challenging –and rather controversial– due to the fact that both the data on deaths and the data on the number of individuals infected are subject to many different biases. We consider a Bayesian evidence synthesis approach which, while simple enough for researchers to understand and use, accounts for many important sources of uncertainty inherent in both the seroprevalence and mortality data. With the understanding that the results of one's evidence synthesis analysis may be largely driven by which studies are included and which are excluded, we conduct two separate parallel analyses based on two lists of eligible studies obtained from two different research teams. The results from both analyses are rather similar. With the first analysis, we estimate the COVID-19 IFR to be 0.37% (95% credible interval of $(0.19\%, 0.61\%)$) for a typical population where 9% of the population is aged over 65 years and where the GDP (at purchasing-power parity (PPP)) per capita is \$17.8k (the approximate worldwide average). With the second analysis, we obtain 0.37% (95% credible interval of $(0.22\%, 0.55\%)$. Our results suggest that, as one might expect, lower IFRs are associated with younger populations (and may also be associated with wealthier populations). For a typical population with the age and wealth of the United States we estimate an IFR of 0.61% and 0.59%; and for a typical population with the age and wealth of the European Union, we obtain IFR estimates of 0.90% and 0.62%. Keywords: COVID-19; evidence synthesis; Bayesian inference; infection fatality rate.

Above all, what's needed is humility in the face of an intricately evolving body of evidence. The pandemic could well drift or shift into something that defies our best efforts to model and characterize it.

> Siddhartha Mukherjee, *The New Yorker* February 22, 2021

1 Introduction

The infection fatality ratio (IFR), defined as the proportion of individuals infected who will go on to die as a result of their infection, is a crucial statistic for understanding SARS-CoV-2 and the ongoing COVID-19 pandemic. Estimating the COVID-19 IFR has proven to be particularly challenging –and rather controversial– due to the fact that both the data on deaths and the data on the number of individuals infected are subject to many different biases.

SARS-CoV-2 seroprevalence studies can help provide a better understanding of the true number of infections in a given population and for this reason several researchers have sought to leverage seroprevalence study data to infer the COVID-19 IFR [\[29\]](#page-20-0). In particular, Ioannidis [\[47\]](#page-21-0), Levin et al.

[\[60\]](#page-23-0), Brazeau et al. [\[21\]](#page-19-0), and O'Driscoll et al. [\[84\]](#page-25-0) have all undertaken analyses, of varying degrees of complexity, in which they combine data from multiple seroprevalence studies with available mortality statistics to derive IFR estimates.

The analyses of both Brazeau et al. [\[21\]](#page-19-0) and O'Driscoll et al. [\[84\]](#page-25-0) are done using rather complex Bayesian models which rely on numerous detailed assumptions. For instance, Brazeau et al. [\[21\]](#page-19-0) use a Bayesian "statistical age-based model that incorporates delays from onset of infection to seroconversion and onset of infection to death, differences in IFR and infection rates by age, and the uncertainty in the serosample collection time and the sensitivity and specificity of serological tests." O'Driscoll et al. [\[84\]](#page-25-0) employ a Bayesian ensemble model which assumes "a gamma-distributed delay between onset [of infection] and death" and assumes different risks of infection for "individuals aged 65 years and older, relative to those under 65." While these analyses go to great lengths to account for the various sources of uncertainty in the data, the complexity of the models will no doubt make it challenging for other researchers to fit these models to different data in a constantly evolving pandemic.

In contrast, the analyses of Ioannidis [\[47\]](#page-21-0) and Levin et al. [\[60\]](#page-23-0) are decidedly more simple. For each seroprevalence study under consideration, Ioannidis [\[47\]](#page-21-0) counts the cumulative number of deaths (from the beginning of the pandemic) until 7 days after the study mid-point (or until the date the study authors suggest), and divides this number of deaths by the estimated number of (previous or current) infections to obtain a study-specific IFR estimate. A "location specific" IFR estimate is then obtained by taking a weighted (by the study's sample size) average of the study-specific IFR estimates for a given location (i.e., for a given country or state). Ioannidis [\[47\]](#page-21-0) then calculates the median of all the location specific IFR estimates. No uncertainty interval for this estimate is provided. As such, it is impossible to determine what level of confidence one should place in Ioannidis [\[47\]](#page-21-0)'s estimates.

The analysis of Levin et al. [\[60\]](#page-23-0) is based on a standard frequentist random-effects meta-analysis model. For each age-group and seroprevalence study under consideration, Levin et al. [\[60\]](#page-23-0) calculate a 95% confidence interval (CI) for a study-specific IFR by counting the cumulative number of deaths up until 4 weeks after the study mid-point and dividing this number of deaths by the estimated upper and lower bounds of the number of infected individuals. The meta-analysis model then combines each of these study-specific IFRs. While this analysis provides standard confidence intervals and is relatively straightforward, it does not take into account certain important sources of uncertainty (to be discussed in Section 2).

The analysis method we propose is simple enough for researchers to easily understand and use, while accounting for important sources of uncertainty inherent in both the seroprevalence data and the mortality data. Similar Bayesian models have been used previously for evidence synthesis of seroprevalence data for other infectious diseases (e.g., Brody-Moore [\[22\]](#page-19-1)).

A major part in any evidence synthesis is determining which studies to consider within the analysis. Determining appropriate inclusion and exclusion criteria for seroprevalence studies is a rather complicated and delicate issue when it comes to estimating the COVID-19 IFR [\[12,](#page-18-0) [48\]](#page-22-0). Reviewing and evaluating the merits of the hundreds of available seroprevalence studies also involves a tremendous amount of review work and time. Fortunately, both Chen et al. [\[28\]](#page-20-1) and Arora et al. [\[6\]](#page-17-0) have done comprehensive and thorough reviews to ascertain study quality (i.e., risk of bias). We will work from these two lists to conduct two separate parallel analyses. This approach –conducting two analyses based on two distinct and independent literature reviews– will allow us to better understand the impact of different inclusion and exclusion criteria [\[35\]](#page-20-2). We will review the data and how it was obtained in Section 3, following a review of the methods in Section 2. In Section 4, we summarize the results of our analysis and conclude in Section 5.

2 Methods

2.1 Bayesian model for evidence synthesis

Suppose we have data from K different seroprevalence studies. Then, for $k = 1, \ldots, K$, let:

- T_k be the total number of individuals tested in the k-th study;
- CC_k be the total number of confirmed cases (of past or current infection) resulting from those tested in the k -th study;
- P_k be the number of individuals at risk of infection in the population of interest for the k-th study; and
- D_k be the total number of observed deaths (cumulative since pandemic onset) in the population of interest that are attributed to infection.

We do not observe the following latent variables; for $k = 1, \ldots, K$, let:

- C_k be the total number of infected people (cases) in the k-th population;
- IR_k be the true infection rate (proportion of the k-th population which has been infected), which is the expected value of C_k/P_k ; and
- IF R_k be the true underlying infection fatality rate, which is the expected value of D_k/C_k (given C_k).

We will make a series of simple binomial assumptions such that, for $k = 1, \ldots, K$:

$$
CC_k \sim Binom(T_k, C_k/P_k),\tag{1}
$$

$$
C_k \sim Binom(P_k, IR_k), \quad \text{and} \tag{2}
$$

$$
D_k|C_k \sim Binom(C_k, IFR_k). \tag{3}
$$

We wish to emphasize the importance of the third " $D|C$ " binomial distribution above. Failing to account for the conditional distribution of the deaths given the cases may lead to inappropriately precise estimates of the IFR. For example, Streeck et al. [\[121\]](#page-29-0) (in their original preprint (*medRxiv*, May 8, 2020)) calculate an uncertainty interval for the IFR by dividing the number of deaths ($D = 7$) by the upper and lower bounds of the 95% CI for the number of infections (95% CI for $C = [1,551, 1]$ 2,389]). Doing so, they obtain a relatively narrow 95% CI for the IFR: [0.29%, 0.45%] (= [7/1,551, 7/2,389]). In the published version of their article (*Nature Communications*, November 17, 2020), an alternative interval "accounting for uncertainty in the number of recorded deaths" is provided. This alternative interval, which essentially takes into account the $D|C$ binomial distribution, is substantially wider: [0.17%; 0.77%]. In a very similar way, Levin et al. [\[60\]](#page-23-0) also fail to take into account the $D|C$ binomial distribution when estimating study-specific IFRs resulting in spuriously precise study-specific IFR estimates.

Having established simple binomial distributions for the study-specific IRs and IFRs, we define a simple random-effects model such that, for $k = 1, \ldots, K$:

$$
g(IFR_k) \sim \mathcal{N}(\theta_0 + \theta_1 Z_{1k} + \theta_2 Z_{2k}, \tau^2), \text{ and}
$$
 (4)

$$
g(IR_k) \sim \mathcal{N}(\beta, \sigma^2),\tag{5}
$$

where θ_0 represents the mean g(infection fatality rate), τ^2 represents between group infection fatality rate heterogeneity, β represents the mean g(infection rate), σ^2 describes the variability in infection rates across the K groups, Z_{1k} and Z_{2k} are covariates of interest that may be related to the infection fatality rate by means of the θ_1 and θ_2 parameters, and g() is a given link function. In our analysis, we define g() as the complimentary log-log link function (cloglog), though there are other sensible choices including the logit and probit functions. As for the two covariates, Z_{1k} and Z_{2k} , we will define these as the centered and scaled logarithm of (1) the proportion of the population aged over 65 years (65 $y\omega_k$), and of (2) the GDP (at purchasing power parity (PPP)) per capita (GDP_k), respectively.

The model is considered within a Bayesian framework requiring the specification of priors for the unknown parameters. Our strategy for priors is to assume weakly informative priors. Beta, Normal, and half-Normal priors (following the recommendations of Gelman et al. [\[36\]](#page-20-3) and Kümmerer et al. [\[57\]](#page-22-1)) are set accordingly: $g^{-1}(\theta) \sim Beta(0.3, 3)$; $g^{-1}(\beta) \sim Beta(1, 30)$; $\theta_1 \sim \mathcal{N}(0, 10)$;

 $\theta_2 \sim \mathcal{N}(0, 10)$; $\sigma \sim \text{half-}\mathcal{N}(0, 10)$; and $\tau \sim \text{half-}\mathcal{N}(0, 10)$. Note that the performance of any Bayesian estimator will depend on the choice of priors and that this choice can substantially influence the posterior when few data are available [\[15,](#page-18-1) [58\]](#page-22-2). In the Supplementary Material [7.4,](#page-50-0) we show results obtained with an alternative set of priors as a sensitivity analysis.

2.2 Uncertainty in infection rates

While some seroprevalence studies report the exact number of individuals tested and the exact number of confirmed cases amongst those tested, to obtain estimates for the infection rate, there are typically numerous adjustments made (e.g., adjusting for imperfect diagnostic test accuracy, adjusting for clustering of individuals within a household). For this reason, the sample size of a given study might not be a reliable indicator of its precision and weighting a study's contribution in an evidence synthesis based solely on its sample size (as in e.g., Ioannidis [\[47\]](#page-21-0)) may not be appropriate.

Rather than work with the raw testing numbers published in the seroprevalence studies, we calculate effective data values for T_k and CC_k based on a binomial distribution that corresponds to the reported 95% CI for the IR. By "inverting uncertainty intervals" in this way, we are able to properly use the adjusted numbers provided. (This is a similar approach to the strategy employed by Kümmerer et al. [\[57\]](#page-22-1).) Tables [2](#page-56-0) and [3](#page-57-0) list the 95% uncertainty intervals obtained from each of the seroprevalence studies in our two parallel analyses and Tables [4](#page-57-1) and [5](#page-58-0) list the corresponding values for T_k and CC_k .

It must be noted that, as Ioannidis [\[47\]](#page-21-0) cautions, it is possible that under our "inverting uncertainty intervals" approach, poorly conducted seroprevalence studies which fail to make proper adjustments (and thereby have spuriously narrower uncertainty intervals) receive more weight in our analysis, while high-quality studies, which make proper adjustments, are unfairly penalized. Ioannidis [\[47\]](#page-21-0) notes that the strategy of "weighting the study-specific infection fatality rates by the sample size of each study" avoids giving more weight to studies "with seemingly narrower confidence intervals because of poor or no adjustments, while still giving more weight to larger studies." Since we are restricting our analysis to only those supposedly high quality seroprevalence studies, we hope to largely avoid this issue. Weighting studies based on their true precision is obviously the goal in any evidence synthesis, and we recognize that this is particularly difficult when so many studies may misrepresent the precision of their estimates [\[19,](#page-19-2) [23\]](#page-19-3).

2.3 Uncertainty in mortality

Matching prevalence estimates with a relevant number of fatalities is a difficult task. Prevalence estimates obtained from a seroprevalence study do not typically correspond to a specific date. Instead, these estimates will correspond to a window of time during which testing occurred. This period may be only a few days for some studies (e.g., 4 days for Petersen et al. [\[90\]](#page-26-0)), but can also

be several weeks or months for others (e.g., 135 days for Ward et al. [\[133\]](#page-31-0)). Tables [2](#page-56-0) and [3](#page-57-0) list the sampling window start and end dates for each of the studies in our two parallel analyses.

Evidently, a longer sampling window will lead to greater uncertainty when it comes to establishing the relevant number of deaths. It can be difficult to account for this uncertainty and analyses will often simply select a specific date at which to count deaths based on some simple rule of thumb. For example, Ioannidis [\[47\]](#page-21-0) considers the number of deaths at 7 days after the mid-point of the sampling window (or as the relevant number of deaths discussed by the seroprevalence study's authors). As another example, Meyerowitz-Katz and Merone [\[73\]](#page-24-0) take the number of deaths as recorded at 10 days after the end of the sampling window. While these two particular analytical choices are not all that different, each may lead to a substantially different number of deaths for a given study if the study was conducted during a period of time during which the number of deaths was rapidly accelerating. Levin et al. [\[60\]](#page-23-0), who consider the number of deaths up until 4 weeks after the sampling window mid-point, acknowledge this limitation noting that: "matching prevalence estimates with subsequent fatalities is not feasible if a seroprevalence study was conducted in the midst of an accelerating outbreak."

In order to account for the uncertainty in selecting the relevant number of deaths for a given seroprevalence study, we propose considering the number of deaths as interval censored data. Tables [4](#page-57-1) and [5](#page-58-0) list numbers for an interval corresponding to the number of deaths recorded 14 days after the start of the sampling window and 14 days after the end of sampling window for each seroprevalence study. While we might not know exactly what number of deaths is most appropriate, we can be fairly confident that the appropriate number lies somewhere within this interval. The 14 day offset allows for the known delay between the onset of infection and death, taking into consideration the delay between the onset of infection and the development of detectable antibodies [\[63,](#page-23-1) [136\]](#page-31-1).

3 The data

3.1 Seroprevalence data

As the COVID-19 pandemic has progressed, a rapidly increasing number of SARS-CoV-2 seroprevalence studies have been conducted worldwide [\[6\]](#page-17-0). However, many of these studies have produced biased estimates or are otherwise unreliable due to a variety of different issues with study design, and/or with data collection, and/or with inappropriate statistical analysis [\[19\]](#page-19-2). We seek to restrict our analysis to high quality studies which used probability-based sampling methods. Such studies are less likely to suffer from substantial biases [\[112\]](#page-28-0). Based on the reviews of Chen et al. [\[28\]](#page-20-1) and of Arora et al. [\[6\]](#page-17-0), we compiled two separate sets of studies for analysis (these are listed in Tables [2](#page-56-0) and [3,](#page-57-0) respectively). With the understanding that the results of an evidence synthesis may be largely

driven by which studies are included/excluded, we will use these two separate sets to conduct two separate analyses.

Figure 1: Flowchart of seroprevalence studies considered for Chen et al. -based analysis (based on the review of Chen et al. [\[28\]](#page-20-1)).

Chen et al. [\[28\]](#page-20-1) reviewed the literature for articles published between December 1, 2019, and December 22, 2020, and identified more than 400 unique seroprevalence studies. For each of these, study quality was established using a scoring system developed on the basis of a seroepidemiological protocol from the Consortium for the Standardization of Influenza Seroepidemiology [\[44\]](#page-21-1). In total, Chen et al. [\[28\]](#page-20-1) identified 38 articles which considered a sample based on a "general population" and which obtained a study quality grade of A or B (see full list in Table S8 of Chen et al. [\[28\]](#page-20-1)). We consider these 38 articles as a starting point for inclusion for our analysis. After excluding those studies which are duplicates (n=2), those that used a "convenience" or "non-probability" based sampling method (according to the classification of Arora et al. [\[6\]](#page-17-0)) (n=8), a study no longer considered accurate based on new information about the accuracy of the antibody test used $(n=1)$, a study that has a very narrowly defined target population (n=1), studies for which relevant death data could not be found (n=5), and studies which did not provide a 95% uncertainty interval (n=2), we were left with a set of $K = 19$ $K = 19$ $K = 19$ studies for analysis; see Figure 1 and details in the Supplementary Material.

Arora et al. [\[6\]](#page-17-0) conducted the Serotracker "living systematic review" of COVID-19 seroprevalence studies whereby the results of the review are continuously updated on <serotracker.com/data>. For each study reviewed, the risk of bias was evaluated based on an assessment using the Joanna

Briggs Institute Critical Appraisal Guidelines for Prevalence studies [\[19,](#page-19-2) [77\]](#page-24-1). For analysis, we consider the 45 studies listed on <serotracker.com/data> (as of June 5, 2021), that are categorized as having a "low risk of bias" and are categorized as targeting "household and community samples." After excluding those studies which are duplicates (n=3), one study that used a "convenience" or "non-probability" based sampling method (according to the classification of Arora et al. [\[6\]](#page-17-0)) (n=1), those studies no longer considered accurate based on new information about the accuracy of the antibody test used $(n=2)$, those that have very narrowly defined target populations $(n=2)$, those for which relevant death data could not be found (n=8), and those which did not provide a 95% uncertainty interval for the estimated prevalence (n=1), we are left with a set of $K = 28$ studies for analysis; see Figure [2](#page-8-0) and details in the Supplementary Material.

Figure 2: Flowchart of seroprevalence studies considered for Serotracker-based analysis (based on the Serotracker review Arora et al. [\[6\]](#page-17-0)).

For each of the seroprevalence studies included in each of the two analysis sets, we recorded the 95% uncertainty interval for the infection rate as reported in the study article. If an article reported on multiple phases of a study (e.g., a longitudinal series of different surveys), or reported different results for different areas instead of an overall estimate (e.g., a series of different estimates for different regions), we selected only the first set of estimates. Furthermore, if a study reported more than one 95% uncertainty interval (e.g., different intervals corresponding to different adjustments and assumptions), we selected the lowest value amongst the different lower bounds and the highest value amongst the different upper bounds. These numbers are recorded in Tables [2](#page-56-0) and [3](#page-57-0) under *IR interval*. Based on these numbers, we calculated effective data values for the number of tests (T_k) and the number of confirmed cases (CC_k) which are listed in Tables [4](#page-57-1) and [5](#page-58-0) alongside population numbers (P_k) and numbers corresponding to the proportion of the population over 65 years old $(65y\omega_k)$ and the GDP (PPP) per capita (GDP_k) ; see Supplemental Material for details and data sources.

3.2 Mortality data

Mortality data was obtained from various sources (e.g., academic, government, health authority); see details in Supplementary Material (Section [7.3\)](#page-37-0). If a seroprevalence study referenced a specific source for mortality data, we used the referenced source for our numbers whenever possible. If no source was referenced or suggested, we considered publicly available data sources.

For many populations, there are concerns that cause of death information may be very inaccurate and lead to biased COVID-19 mortality statistics. To overcome this issue, many suggest looking to "excess deaths" by comparing aggregate data for all-cause deaths from the time during the pandemic to the years prior [\[59\]](#page-23-2). For populations with a large discrepancy between the number of deaths attributed to COVID-19 and the number of excess deaths –as suggested, when possible, by a large undercount ratio (UCR) derived by Karlinsky and Kobak [\[51\]](#page-22-3)– we used numbers based on excess deaths if these were available.

India, Pakistan, Palestine, Ethiopia, and China are the only countries represented in the studies that we assessed for data availability that are not included in Karlinsky and Kobak [\[51\]](#page-22-3)'s analysis. There is evidence of substantial under-reporting of COVID-19 deaths in India [\[10,](#page-18-2) [94\]](#page-26-1) while little can be gathered about the reliability of official mortality data for Pakistan, Palestine^{[1](#page-0-0)}, Ethiopia^{[2](#page-0-0)}, China (but do see [\[65\]](#page-23-3) and [\[126\]](#page-30-0)). As such, we will exclude the Qutob et al. [\[96\]](#page-26-2) ("Palestinian population residing in the West Bank") and He et al. [\[42\]](#page-21-2) ("Wuhan, China") studies from our the Serotracker-based analysis and will exclude the Alemu et al. [\[1\]](#page-17-1) ("Addis Ababa, Ethiopia") and the Nisar et al. [\[83\]](#page-25-1) ("Two neighborhoods of Karachi, Pakistan") studies from the Chen et al.-based analysis.

For India, Mukherjee et al. [\[76\]](#page-24-2) and Purkayastha et al. [\[95\]](#page-26-3) estimate UCRs for the entire country as well as for each individual Indian state and union territory. We will use these UCRs to adjust the death numbers for seroprevalence studies in India (see Supplementary Material for details). There are two countries represented within our data that are identified by Karlinsky and Kobak [\[51\]](#page-22-3) as having large discrepancies between the official number of deaths attributed to COVID-19 and the number of excess deaths Iran (with UCR=2.4) and Russia (with UCR=4.5). As such, for the

¹Official regional death numbers for Palestine are available from the Palestinian government dashboard (see <https://corona.ps/details>; accessed July 28, 2021).

²Official regional death numbers for Ethiopia have been made available previously (e.g., [http://web.](http://web.archive.org/web/2020*/https://www.covid19.et/covid-19/) [archive.org/web/2020*/https://www.covid19.et/covid-19/](http://web.archive.org/web/2020*/https://www.covid19.et/covid-19/) and the Twitter account: [https://twitter.](https://twitter.com/Harun_Asefa/status/1259069832877793280) [com/Harun_Asefa/status/1259069832877793280](https://twitter.com/Harun_Asefa/status/1259069832877793280); accessed August 4, 2021).

Barchuk et al. [\[11\]](#page-18-3) ("Saint Petersburg, Russia") and for the Khalagi et al. [\[52\]](#page-22-4) ("Iran" study), we will use numbers based on excess deaths (see Supplementary Material for details).

Finally, note that several western governments report deaths that occurred in long-term care facilities (also known as "nursing homes" or, in France as "Établissement d'hébergement pour personnes âgées dépendantes" (EHPAD)) separately. Specifically, for Warszawski et al. [\[134\]](#page-31-2), Chan et al. [\[27\]](#page-20-4), and Mahajan et al. [\[67\]](#page-23-4) the mortality and prevalence data exclude those living in long-term care facilities (see Supplementary Material for details). Given the particularly devastating impact that COVID-19 has had on residents of long-term care facilities [\[39,](#page-21-3) [108\]](#page-28-1), our IFR estimates may be biased somewhat downwards as a result these exclusions; see Axfors and Ioannidis [\[7\]](#page-17-2).

4 Results

The model as described in Section 2, was fit to the two datasets as described in Section 3. We fit the model using JAGS (just another Gibbs sampler) [\[56\]](#page-22-5), with 5 independent chains, each with 1 million draws (20% burn-in, thinning of 100); see Supplementary Material (Section [7.5\)](#page-55-0) for details and JAGS code.

We report posterior median estimates and 95% highest probability density (HPD) credible intervals (CrI). Figure [3](#page-13-0) (for the Chen et al.-based analysis) and Figure [4](#page-14-0) (for the Serotracker-based analysis) plot the point estimates and credible intervals obtained for IFR_k , for k in 1, ..., K, respectively. In these figures the seroprevalence studies are listed in order of their "fitted" IFR values (the posterior median of $g^{-1}(\theta_0 + \theta_1 Z_{1k} + \theta_2 Z_{2k})$, for k in 1, ..., K, marked on the plot by the \times symbols). Results obtained for the other model parameters are listed in Table [1.](#page-11-0)

In general, the Chen et al.-based analysis and the Serotracker-based analysis provide mostly similar results. Notably, the Serotracker-based analysis considers a much more geographically diverse set of seroprevalence studies and several studies that appear to be prominent outliers (e.g., "Lima, Peru", "Utsunomiya City, Japan", and "Castiglione d'Adda, Italy", see Figure [4\)](#page-14-0). With regards to heterogeneity, fitting the model without any covariates, one obtains $\hat{\tau} = 0.55$ (Chen et al.-based analysis) and $\hat{\tau} = 0.95$ (Serotracker-based analysis). This suggests that the two covariates, $65y\sigma_k$ and GDP_k , account for approximately 50% (= $(0.55^2 - 0.39^2) / (0.55^2)$; Chen et al.-based analysis) and $15\% = (0.93^2 - 0.86^2)/(0.93^2)$ $15\% = (0.93^2 - 0.86^2)/(0.93^2)$ $15\% = (0.93^2 - 0.86^2)/(0.93^2)$; Serotracker-based analysis) of the heterogeneity in the IFR.³ Our estimates of $\hat{\theta}_1 = 0.59$ (Chen et al.-based analysis) and $\hat{\theta}_1 = 0.25$ (Serotracker-based analysis) suggest that older populations are more likely to have higher IFRs. This is as expected since age is

³For reference, Levin et al. [\[60\]](#page-23-0) conclude that 87% of the heterogeneity in the IFR can be explained by variations in age composition and age-specific prevalence of COVID-19. However, note that the linear regression analysis used to obtain this 87% result is done without an intercept term (see Levin et al. [\[60\]](#page-23-0) - Figure 6). A linear regression with intercept results in a value of 43%. The intraclass correlation coefficient (ICC) [\[129\]](#page-30-1) between Levin et al. [\[60\]](#page-23-0)'s predicted IFRs and the observed IFRs is 0.65 (after removing one outlier, "Portugal"), suggesting that the extent of agreement is reasonably high but nowhere near perfect.

Parameter	Chen et al. analysis	Serotracker analysis
θ_0	-5.19 , with 95% CrI of $(-5.44, -4.95)$	-5.34 , with 95% CrI of $(-5.71, -4.99)$
θ_1	0.59, with 95% CrI of $(0.22, 0.92)$	0.25, with 95% CrI of $(-0.53, 0.99)$
θ_{2}	-0.17 with 95% CrI of $(-0.52, 0.21)$	\vert 0.14, with 95% CrI of (-0.62, 0.90)
τ	0.39 with 95% CrI of $(0.20, 0.66)$	0.86, with 95% CrI of $(0.56, 1.22)$
σ	1.14 with 95% CrI of $(0.78, 1.62)$	1.50, with 95% CrI of (1.10, 1.99)

Table 1: Parameter estimates obtained from the Chen et al.-based analysis and the Serotracker-based analysis.

known to be a very important risk factor [\[135,](#page-31-3) [138\]](#page-31-4). Our estimate of $\hat{\theta}_2 = -0.17$ (Chen et al.-based analysis) would suggest that wealthier populations may be more likely to have lower IFRs. However, the estimate obtained from the Serotracker-based analysis ($\hat{\theta}_2 = 0.14$) as well as the wide credible intervals obtained for the θ_2 parameter (in both analyses) suggest a much less definitive conclusion. There are several reasons which might explain this result. As with any observational data analysis, the estimate of θ_2 may suffer from bias due to unobserved confounding and statistical power may be compromised by the presence of outliers and insufficient heterogeneity in the GDP per capita metric across the different populations included in our analyses.

We can infer (by determining the posterior median of $g^{-1}(\theta_0 + \theta_1 z_{1*} + \theta_2 z_{2*})$, for selected values of z1[∗] and z2[∗]) the *typical* IFR amongst populations (be they included in our study or not) having a given proportion of the populace aged over 65 and a given GDP per capita. Thus we calculate posterior point and interval estimates corresponding to age and wealth values that match the population of the entire world (World), the United States (USA), and the European Union (EU) (as listed by the World Bank's World Development Indicators (WDI)); see "World", "USA", and "EU" rows in Figures [3](#page-13-0) and [4.](#page-14-0) For $65y0 = 9\%$ and GDP = \$17,811, the approximate worldwide values, we obtain, from the Chen et al.-based analysis, an across-population average IFR estimate of 0.37%, with a 95% CrI of (0.19%, 0.61%). With the Serotracker-based analysis, we obtain a similar estimate of 0.37%, with a 95% CrI of $(0.22\%, 0.55\%)$. For 65yo = 16% and GDP = \$65,298, the USA values, we obtain across-population average IFR estimates of 0.61%, with a 95% CrI of (0.47%, 0.78%) (Chen et al.-based analysis) and of 0.59%, with a 95% CrI of (0.32%, 0.94%) (Serotracker-based analysis). Finally, for $65yo = 20\%$ and $GDP = $47,828$, the EU values, we obtain across-population average IFR estimates 0.90%, with a 95% CrI of (0.60%, 1.21%) (Chen et al.-based analysis) and of 0.62%, with a 95% CrI of (0.35%, 0.96%) (Serotracker-based analysis).

While the infection-rate estimates obtained from the seroprevalence studies should be relatively reliable (due to having satisfied the risk of bias assessments of either Chen et al. [\[28\]](#page-20-1) or Arora et al. [\[6\]](#page-17-0)), the mortality data we collected may be less reliable depending on the target population and source. The data which were not obtained directly from official and reliable sources may be particularly suspect. With this in mind, as a sensitivity analysis, we repeated both analyses with

these data excluded; see results in Figures [5](#page-51-0) and [6](#page-52-0) in the Supplementary Material. Without the excluded studies, we are unable to provide a reasonable "World" estimate (see the extremely wide credible intervals). However, the "USA" and "EU" estimates are left relatively unchanged. We also repeated the two analyses using a different set of priors to verify that our results were not overly sensitive to our particular choice of priors. The results of this alternative analysis are very similar to the results of our original analyses; see Figures [7](#page-53-0) and [8](#page-54-0) in the Supplementary Material.

Our estimates are somewhat similar to those obtained in other analyses. Brazeau et al. [\[21\]](#page-19-0), using data from 10 representative seroprevalence studies (identified after screening 175 studies), infer "the overall IFR in a typical low-income country, with a population structure skewed towards younger individuals, to be 0.23% (0.14%-0.42% 95% prediction interval range)." For a "typical high income country, with a greater concentration of elderly individuals," Brazeau et al. [\[21\]](#page-19-0) obtain an estimate of 1.15% (95% prediction interval of 0.78%-1.79%). Ioannidis [\[47\]](#page-21-0), using data from seroprevalence studies with sample sizes greater than 500, obtains a "median infection fatality rate across all 51 locations" of 0.27% and (and of 0.23% following an ad-hoc correction to take into account "that only one or two types of antibodies" may have been tested in some seroprevalence studies). Levin et al. [\[60\]](#page-23-0), who restricted their analysis to populations in "advanced economies," do not provide an overall IFR, but instead (perhaps more appropriately) provide age-group specific estimates. For the 45–54 year old age group, Levin et al. [\[60\]](#page-23-0) estimate the IFR to be 0.23% (95% CI of 0.20% – 0.26%), and for the 55–64 year old age group, 0.75% (95% CI of 0.66%–0.87%). Sullivan et al. [\[124\]](#page-30-2) estimate that for the United States, the IFR for adults is 0.85% (95% CrI of 0.76%-0.97%) based on a nationwide seroprevalence survey conducted between August and December, 2020.^{[4](#page-0-0)} Pei et al. [\[87\]](#page-25-2) using a rather complex Bayesian "metapopulation" model conclude that, for the United States during 2020, the IFR likely "decreased from around 1% in March to about 0.25% in December." For comparison, our "USA" estimates of 0.61% and of 0.59% are based on data obtained mostly between April, 2020 and August, 2020 (see Tables [2](#page-56-0) and [3\)](#page-57-0).

5 Conclusion

Estimation of the IFR can be incredibly challenging due to the fact that it is a ratio of numbers where both the numerator and the denominator are subject to a wide range of biases. Our proposed method seeks to address some of these biases in a straightforward manner.

With regards to the numerator, we considered the number of deaths as interval censored data so as to account for the uncertainty in selecting the most relevant number of deaths. While we consider this an improvement over other methods that use a single fixed number, we acknowledge that the specific choice of a 14 day offset is somewhat arbitrary and that the data for deaths also suffer from

⁴While Sullivan et al. [\[124\]](#page-30-2) used a nation-wide representative sampling frame, the results may be subject to selection bias given the low response rate of only 12.6%.

Figure 3: Results from the Chen et al.-based analysis: posterior median estimates for the IFR_k variables (for $k = 1, \ldots, 18$) with 95% HPD CrIs. Studies are listed from top to bottom in order of increasing fitted values (these values are indicated by \times). Also plotted, under the labels "World (65 yo=9%, GDP=17.8k)", "USA (65 yo=16%, GDP=65.3k)", "EU (65 yo=20%, GDP=47.8k)", are the posterior median estimate and 95% HPD CrIs for the typical IFR corresponding to values for the proportion of the population aged 65 years and older of 9% and for GDP per capita of \$17,811 (the worldwide values), of 16% and of \$65,298 (the USA values), and of 20% and of \$47,828 (the EU values).

Figure 4: Results from the Serotracker-based analysis: posterior median estimates for the IFR_k variables (for $k = 1, \ldots, 18$) with 95% HPD CrIs. Studies are listed from top to bottom in order of increasing fitted values (these values are indicated by \times). Also plotted, under the labels "World (65) yo=9%, GDP=17.8k)", "USA (65 yo=16%, GDP=65.3k)", "EU (65 yo=20%, GDP=47.8k)", are the posterior median estimate and 95% HPD CrIs for the typical IFR corresponding to values for the proportion of the population aged 65 years and older of 9% and for GDP per capita of \$17,811 (the worldwide values), of 16% and of \$65,298 (the USA values), and of 20% and of \$47,828 (the EU values).

other sources of bias. Ioannidis [\[48\]](#page-22-0) notes that the time between infection and death may vary substantially "and may be shorter in developing countries where fewer people are long-sustained by medical support." We used mortality data based on "excess deaths" statistics for Russia and Iran, since official mortality statistics appeared to be highly inaccurate. We also adjusted official numbers for India based on the best available information. These adjustments are certainly not perfect and we note that "excess deaths" statistics may also suffer from substantial inaccuracies [\[75\]](#page-24-3).

With regards to the denominator, we looked to data from "high-quality" seroprevalence studies in an effort to avoid biased estimates. However, these data are also not perfect. Seroprevalence studies are severely limited by the representativeness of the individuals they test. Certain groups of individuals are unlikely to be tested in a seroprevalence study and these groups often have very high infection rates (e.g., institutionalized populations, hospitalized populations, homeless people). On the other hand, those individuals who have reason to believe they may have been infected, may be more likely to volunteer to participate in a seroprevalence study [\[112\]](#page-28-0). It is also likely that seroreversion (loss of detectable antibodies over time) may lead to a seroprevalence study underestimating the true number of infections if the time between the main outbreak and the subsequent antibody testing is substantial [\[88\]](#page-26-4). Notably, Axfors and Ioannidis [\[7\]](#page-17-2) employ a "X-fold"-based correction factor to adjust seroprevalence estimates for this type of bias.

The need to improve the quality and reporting of seroprevalence studies cannot be overemphasized.^{[5](#page-0-0)} A major limitation of evidence synthesis is often summarized by the expression "garbage in, garbage out" [\[31\]](#page-20-5), meaning that if one includes biased studies in one's analysis, the analysis results will themselves be biased [\[111\]](#page-28-2). In our two analyses, we only included data from 19 and 28 out of potentially hundreds of seroprevalence studies due primarily to the fact that so few studies were considered reliable and at low risk of bias. Excluding low-quality/biased studies from our analysis was necessary, at least to a certain degree, in order to obtain valid estimates. However, as a consequence of our strict exclusion criteria, much of the world's population is severely underrepresented in our data. If the quality of studies were to be correlated with unmeasured factors that impact the IFR, excluding studies based on their perceived quality could lead to unmeasured confounding at a meta-analytic level [\[49\]](#page-22-6). Novel methods which allow evidence syntheses to appropriately incorporate biased data are urgently needed. Recently, Campbell et al. [\[25\]](#page-19-4) proposed a partially identified model to combine seroprevalence study data with data from official statistics that are known to be biased due to "preferential testing."

Outside of biased data, perhaps the foremost challenge in evidence synthesis using observational data is that necessarily one is forced to make an array of design choices around inclusion/exclusion

⁵Bobrovitz et al. [\[19\]](#page-19-2) conclude that a majority of COVID-19 seroprevalence studies are "at high risk of bias [...], often for not statistically correcting for demographics or for test sensitivity and specificity, using non-probability sampling methods, and using non-representative sample frames." Shook-Sa et al. [\[112\]](#page-28-0) note that "it is very difficult to estimate the level of bias introduced by convenience sampling."

criteria, statistical modeling approaches, and prior specifications [\[35\]](#page-20-2). With the two separate analyses and the various additional sensitivity analyses, we were quite encouraged by the stability of our results to perturbations of these inputs.

Reducing the uncertainty around the severity of COVID-19 was of great importance to policy makers and the public during the early stages of the pandemic [\[32,](#page-20-6) [46,](#page-21-4) [64\]](#page-23-5) and immense efforts have been made in the collection and analysis of data (e.g., Williamson et al. [\[135\]](#page-31-3)). And yet, even after more than a year, there is still a large amount of uncertainty and unexplained heterogeneity surrounding the COVID-19 IFR, particularly with respect to populations in less affluent countries. While a certain amount of heterogeneity is to be expected [\[43\]](#page-21-5), identifying factors associated with higher IFRs is the ultimate goal and investigating potential variables that can account for the observed heterogeneity may lead to important insights [\[16,](#page-18-4) [49\]](#page-22-6).

We prioritized simplicity in our modeling so as to promote transparency in our findings, and to facilitate adaptations to similar, but not identical, data structures. While "simple" is a relative term, note that the entire dataset used for our analyses fits on a single page (in Tables [4](#page-57-1) and [5\)](#page-58-0) and that the entire JAGS MCMC code fits on less than a single page (see Supplementary Material). One model extension that could be pursued would involve age stratification of IFR. Age-group specific prevalence/mortality data is available for many geographic areas Riffe et al. [\[102\]](#page-27-0) and such data could inform an extended version of our model, thereby offering an alternative to the approach described by Levin et al. [\[60\]](#page-23-0) for estimating age-group specific IFRs.

Finally, we must emphasize that the IFR is a moving target. As the pandemic changes, so to does the IFR. Our estimates are based on data from 2020, some of which were obtained more than a year ago. It is likely that, with continual viral mutation of SARS-CoV-2 and advances in treatment, the current IFR in many places is now markedly different than it was earlier in 2020 [\[87,](#page-25-2) [91,](#page-26-5) [131\]](#page-30-3).

6 Declarations

Funding - This work was supported by the European Union's Horizon 2020 research and innovation programme under ReCoDID grant agreement No 825746 (\blacksquare) and by the Canadian Institutes of Health Research, Institute of Genetics (CIHR-IG) under Grant Agreement No 01886- 000.

Conflicts of interest/Competing interests - None declared.

Availability of data and material - Data used for the analysis is available in the Supplementary Material and at <https://github.com/harlanhappydog/BayesianSeroMetaAnalysis>.

Code availability - Code used for the analysis is available in the Supplementary Material and at <https://github.com/harlanhappydog/BayesianSeroMetaAnalysis>.

Availability of data and material - Data used for the analysis is available in the Supplementary Material and at <https://github.com/harlanhappydog/BayesianSeroMetaAnalysis>.

References

- [1] Berhanu Nega Alemu, Adamu Addissie, Gemechis Mamo, Negussie Deyessa, Tamrat Abebe, Abdulnasir Abagero, Wondimu Ayele, Workeabeba Abebe, Tewodros Haile, Rahel Argaw, Wondwossen Amogne, Ayele Belachew, Zelalem Desalegn, Brhanu Teka, Eva Kantelhardt, Mesfin Wossen, Saro Abdella, Getachew Tollera, and Lia Tadesse. Seroprevalence of anti-SARS-CoV-2 antibodies in Addis Ababa, Ethiopia. *bioRxiv*, 2020. doi[:10.1101/2020.10.13.337287.](https://doi.org/10.1101/2020.10.13.337287)
- [2] Carlos Álvarez-Antonio, Graciela Meza-Sánchez, Carlos Calampa, Wilma Casanova, Cristiam Carey, Freddy Alava, Hugo Rodríguez-Ferrucci, and Antonio M Quispe. Seroprevalence of anti-sars-cov-2 antibodies in iquitos, peru in july and august, 2020: a population-based study. *The Lancet Global Health*, 9(7):e925–e931, 2021.
- [3] Carlos Álvarez-Antonio, Graciela Meza-Sánchez, Carlos Calampa, Wilma Casanova, Cristiam Carey, Freddy Alava, Hugo Rodríguez-Ferrucci, and Antonio Marty Quispe. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Loreto, Peru. *medrxiv*, 2021.
- [4] Abhishek Anand, Justin Sandefur, and Arvind Subramanian. Three new estimates of India's all-cause excess mortality during the COVID-19 pandemic. [https://www.cgdev.org/publication/](https://www.cgdev.org/publication/three-new-estimates-indias-all-cause-excess-mortality-during-covid-19-pandemic) [three-new-estimates-indias-all-cause-excess-mortality-during-covid-19-pandemic](https://www.cgdev.org/publication/three-new-estimates-indias-all-cause-excess-mortality-during-covid-19-pandemic), 2021.
- [5] Ayesha Appa, Saki Takahashi, Isabel Rodriguez-Barraquer, Gabriel Chamie, Aenor Sawyer, Elias Duarte, Jill Hakim, Keirstinne Turcios, Joanna Vinden, Owen Janson, et al. Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community. In *Open Forum Infectious Diseases*, 2020.
- [6] Rahul K Arora, Abel Joseph, Jordan Van Wyk, Simona Rocco, Austin Atmaja, Ewan May, Tingting Yan, Niklas Bobrovitz, Jonathan Chevrier, Matthew P Cheng, et al. Serotracker: a global SARS-CoV-2 seroprevalence dashboard. *The Lancet Infectious Diseases*, 21(4): e75–e76, 2021.
- [7] Cathrine Axfors and John PA Ioannidis. Infection fatality rate of COVID-19 in communitydwelling populations with emphasis on the elderly: An overview. *medRxiv*, 2021.

- [8] Insa Backhaus, Nico Dragano, Friedrich Boege, Klaus Göbels, Derik Hermsen, Nadine Lübke, and Jörg Timm. First results of the serodus study. $https://www.$ [uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/](https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus) [institut-fuer-medizinische-soziologie/das-institut/forschung/serodus](https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus), 2021.
- [9] Kristina L Bajema, F Scott Dahlgren, Travis W Lim, Nicolette Bestul, Holly M Biggs, Jacqueline E Tate, Claudio Owusu, Christine M Szablewski, Cherie Drenzek, Jan Drobeniuc, et al. Comparison of estimated severe acute respiratory syndrome coronavirus 2 seroprevalence through commercial laboratory residual sera testing and a community survey. *Clinical Infectious Diseases*, 2020.
- [10] Murad Banaji. Estimating COVID-19 infection fatality rate in Mumbai during 2020. *medRxiv*, 2021.
- [11] Anton Barchuk, Dmitriy Skougarevskiy, Kirill Titaev, Daniil Shirokov, Yulia Raskina, Anastasia Novkunkskaya, Petr Talantov, Artur Isaev, Ekaterina Pomerantseva, Svetlana Zhikrivetskaya, et al. Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study. medRxiv, 2020.
- [12] Hilda Bastian. Peering through the smoke at a duel over COVID's infection fatality rate. [https://absolutelymaybe.plos.org/2021/05/31/](https://absolutelymaybe.plos.org/2021/05/31/peering-through-the-smoke-at-a-duel-over-covids-infection-fatality-rate/) [peering-through-the-smoke-at-a-duel-over-covids-infection-fatality-rate/](https://absolutelymaybe.plos.org/2021/05/31/peering-through-the-smoke-at-a-duel-over-covids-infection-fatality-rate/), 2021.
- [13] Adeline Beaumont, Cécile Durand, Martine Ledrans, Valérie Schwoebel, Harold Noel, Yann Le Strat, Donatien Diulius, Léa Colombain, Marie Médus, Philippe Gueudet, et al. High seroprevalence of anti-sARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in Perpignan, France. *medRxiv*, 2021.
- [14] Eran Bendavid, Bianca Mulaney, Neeraj Sood, Soleil Shah, Emilia Ling, Rebecca Bromley-Dulfano, Cara Lai, Zoe Weissberg, Rodrigo Saavedra, James Tedrow, et al. COVID-19 antibody seroprevalence in Santa Clara County, California. *medRxiv*, 2020.
- [15] James O Berger. *Statistical decision theory and Bayesian analysis*. Springer Science & Business Media, 2013.
- [16] Josse A Berlin. Invited commentary: benefits of heterogeneity in meta-analysis of data from epidemiologic studies. *American Journal of Epidemiology*, 142(4):383–387, 1995.
- [17] Rupam Bhattacharyya, Ritoban Kundu, Ritwik Bhaduri, Debashree Ray, Lauren J Beesley, Maxwell Salvatore, and Bhramar Mukherjee. Incorporating false negative tests in epidemio-

logical models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates. *Scientific reports*, 11(1):1–14, 2021.

- [18] Holly M Biggs, Jennifer B Harris, Lucy Breakwell, F Scott Dahlgren, Glen R Abedi, Christine M Szablewski, Jan Drobeniuc, Nirma D Bustamante, Olivia Almendares, Amy H Schnall, et al. Estimated community seroprevalence of SARS-CoV-2 antibodies—two Georgia counties, April 28–May 3, 2020. *Morbidity and Mortality Weekly Report*, 69(29):965, 2020.
- [19] Niklas Bobrovitz, Rahul Krishan Arora, Christian Cao, Emily Boucher, Michael Liu, Hannah Rahim, Claire Donnici, Natasha Ilincic, Nathan Duarte, Jordan Van Wyk, et al. Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis. *medRxiv*, 2020.
- [20] Lysandro Pinto Borges, Aline Fagundes Martins, Monica Santos de Melo, Makson Gleyd- ˆ son Brito de Oliveira, José Melquiades de Rezende Neto, Marcos Barbosa Dósea, Bruna Cecília Maia Cabral, Rafael Fontes Menezes, Aryanne Araujo Santos, Igor Leonardo Santos Matos, et al. Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil. *Revista Panamericana de Salud Publica ´* , 44, 2020.
- [21] N Brazeau, Robert Verity, Sara Jenks, Han Fu, Charles Whittaker, Peter Winskill, Ilaria Dorigatti, Patrick Walker, Steven Riley, Ricardo P Schnekenberg, et al. Report 34: COVID-19 infection fatality ratio: estimates from seroprevalence. [https://www.imperial.ac.uk/](https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-34-ifr/) [mrc-global-infectious-disease-analysis/covid-19/report-34-ifr/](https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-34-ifr/), 2020.
- [22] Peter Brody-Moore. Bayesian hierarchical meta-analysis of asymptomatic Ebola seroprevalence. CMC Senior Theses. 2228. [https://scholarship.claremont.edu/cmc_theses/](https://scholarship.claremont.edu/cmc_theses/2228) [2228](https://scholarship.claremont.edu/cmc_theses/2228), 2019.
- [23] Naomi C Brownstein and Yian Ann Chen. Predictive values, uncertainty, and interpretation of serology tests for the novel coronavirus. *Scientific Reports*, 11(1):1–12, 2021.
- [24] Tim A Bruckner, Daniel M Parker, Scott M Bartell, Veronica M Vieira, Saahir Khan, Andrew Noymer, Emily Drum, Bruce Albala, Matthew Zahn, and Bernadette Boden-Albala. Estimated seroprevalence of SARS-CoV-2 antibodies among adults in Orange County, California. *Scientific Reports*, 11(1):1–9, 2021.
- [25] Harlan Campbell, Perry de Valpine, Lauren Maxwell, Valentijn MT de Jong, Thomas Debray, Thomas Jänisch, and Paul Gustafson. Bayesian adjustment for preferential testing in estimating the COVID-19 infection fatality rate: Theory and methods. arXiv - preprint arXiv:2005.08459, 2020.
- [26] Fabrice Carrat, Xavier de Lamballerie, Delphine Rahib, Helene Blanche, Nathanael Lapidus, Fanny Artaud, Sofiane Kab, Adeline Renuy, Fabien Szabo de Edelenyi, Laurence Meyer,

et al. Seroprevalence of SARS-CoV-2 among adults in three regions of france following the lockdown and associated risk factors: a multicohort study. *medRxiv*, 2020.

- [27] Philip A Chan, Ewa King, Yizhen Xu, William Goedel, Leanne Lasher, Matt Vargas, Ken Brindamour, Richard Huard, Ailis Clyne, James McDonald, et al. Seroprevalence of SARS-CoV-2 antibodies in Rhode Island from a statewide random sample. *American Journal of Public Health*, 111(4):700–703, 2021.
- [28] Xinhua Chen, Zhiyuan Chen, Andrew S Azman, Xiaowei Deng, Ruijia Sun, Zeyao Zhao, Nan Zheng, Xinghui Chen, Wanying Lu, Tingyu Zhuang, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. *The Lancet Global Health*, 9(5):E598–E609, 2021.
- [29] Hannah Clapham, James Hay, Isobel Routledge, Saki Takahashi, Marc Choisy, Derek Cummings, Bryan Grenfell, C Jessica E Metcalf, Michael Mina, Isabel Rodriguez Barraquer, et al. Seroepidemiologic study designs for determining SARS-CoV-2 transmission and immunity. *Emerging Infectious Diseases*, 26(9):1978, 2020.
- [30] Owen Dyer. Covid-19: Peru's official death toll triples to become world's highest. *The BMJ*, 373(n1442), 2021.
- [31] Hans J Eysenck. An exercise in mega-silliness. *American Psychologist*, 33(5):517, 1978.
- [32] Jeremy Samuel Faust. Comparing COVID-19 deaths to flu deaths is like comparing apples to oranges. Scientific American, https://tinyurl.com/ydxx8el8, 2020.
- [33] Barbara Fraser. COVID-19 strains remote regions of peru. *The Lancet*, 395(10238):1684, 2020.
- [34] Anne Gégout-Petit, Hélène Jeulin, Karine Legrand, Agathe Bochnakian, Pierre Vallois, Evelyne Schvoerer, and Francis Guillemin. Seroprevalence of SARS-CoV-2, symptom profiles and seroneutralization during the first COVID-19 wave in a suburban area, France. *medRxiv*, 2021.
- [35] Andrew Gelman and Eric Loken. The garden of forking paths: Why multiple comparisons can be a problem, even when there is no "fishing expedition" or "p-hacking" and the research hypothesis was posited ahead of time. *Department of Statistics, Columbia University*, 348, 2013.
- [36] Andrew Gelman et al. Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper). *Bayesian Analysis*, 1(3):515–534, 2006.
- [37] Mahan Ghafari, Alireza Kadivar, and Aris Katzourakis. Excess deaths associated with the Iranian COVID-19 epidemic: a province-level analysis. *medRxiv*, 2020.

- [38] Govern d'Andorra. Els tests d'anticossos permeten diagnosticar 78 positius de la COVID-19, que podrien haver contagiat unes 360 persones. <https://tinyurl.com/dybe27uk>, 2020.
- [39] David C Grabowski and Vincent Mor. Nursing home care in crisis in the wake of COVID-19. *JAMA*, 324(1):23–24, 2020.
- [40] Daniel F Gudbjartsson, Gudmundur L Norddahl, Pall Melsted, Kristbjorg Gunnarsdottir, Hilma Holm, Elias Eythorsson, Asgeir O Arnthorsson, Dadi Helgason, Kristbjorg Bjarnadottir, Ragnar F Ingvarsson, et al. Humoral immune response to SARS-CoV-2 in Iceland. *New England Journal of Medicine*, 383(18):1724–1734, 2020.
- [41] Pedro C Hallal, Fernando P Hartwig, Bernardo L Horta, Mariangela F Silveira, Claudio J ˆ Struchiner, Luís P Vidaletti, Nelson A Neumann, Lucia C Pellanda, Odir A Dellagostin, Marcelo N Burattini, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. *The Lancet Global Health*, 8(11): e1390–e1398, 2020.
- [42] Zhenyu He, Lili Ren, Juntao Yang, Li Guo, Luzhao Feng, Chao Ma, Xia Wang, Zhiwei Leng, Xunliang Tong, Wang Zhou, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. *The Lancet*, 397(10279):1075–1084, 2021.
- [43] Julian PT Higgins. Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. *International Journal of Epidemiology*, 37(5):1158–1160, 2008.
- [44] Peter W Horby, Karen L Laurie, Benjamin J Cowling, Othmar G Engelhardt, Katharine Sturm-Ramirez, Jose L Sanchez, Jacqueline M Katz, Timothy M Uyeki, John Wood, Maria D Van Kerkhove, et al. Consise statement on the reporting of seroepidemiologic studies for influenza (roses-i statement): an extension of the strobe statement. *Influenza and other respiratory viruses*, 11(1):2–14, 2017.
- [45] Charles Huamaní, Lucio Velasquez, Sonia Montes, Ana Mayanga-Herrera, and Antonio Bernabe-Ortiz. Population-based seroprevalence of SARS-CoV-2 antibodies in a highaltitude setting in Peru. *Available at SSRN 3760458*, 2021.
- [46] John P.A. Ioannidis. First Opinion: A fiasco in the making? as the coronavirus pandemic takes hold, we are making decisions without reliable data. STAT, [https://tinyurl.com/](https://tinyurl.com/uj539o4) [uj539o4](https://tinyurl.com/uj539o4), 2020.
- [47] John PA Ioannidis. Infection fatality rate of COVID-19 inferred from seroprevalence data. *Bulletin of the World Health Organization*, 99(1):19, 2021.

- [48] John PA Ioannidis. Reconciling estimates of global spread and infection fatality rates of COVID-19: an overview of systematic evaluations. *European Journal of Clinical Investigation*, page e13554, 2021.
- [49] John PA Ioannidis and Joseph Lau. Can quality of clinical trials and meta-analyses be quantified? *The Lancet*, 352(9128):590, 1998.
- [50] Sitanshu Sekhar Kar, Sonali Sarkar, Sharan Murali, Rahul Dhodapkar, Noyal Mariya Joseph, and Rakesh Aggarwal. Prevalence and time trend of SARS-CoV-2 infection in Puducherry, India, August–October 2020. *Emerging Infectious Diseases*, 27(2):666, 2021.
- [51] Ariel Karlinsky and Dmitry Kobak. Tracking excess mortality across countries during the covid-19 pandemic with the world mortality dataset. *eLife*, 10:e69336, jun 2021. ISSN 2050-084X. doi[:10.7554/eLife.69336.](https://doi.org/10.7554/eLife.69336) URL <https://doi.org/10.7554/eLife.69336>.
- [52] Kazem Khalagi, Safoora Gharibzadeh, Davood Khalili, Mohammad Ali Mansournia, Siamak Mirab Samiee, Saeide Aghamohamadi, Maryam Mir-Mohammad-Ali Roodaki, Seyed Mahmoud Hashemi, Katayoun Tayeri, Hengameh Namdari Tabar, et al. Prevalence of COVID-19 in iran: Results of the first survey of the iranian covid-19 serological surveillance program. *Clinical Microbiology and Infection*, 2021.
- [53] Jahidur Rahman Khan, Nabil Awan, Md Islam, Olav Muurlink, et al. Healthcare capacity, health expenditure, and civil society as predictors of COVID-19 case fatalities: A global analysis. *Frontiers in Public Health*, 8:347, 2020.
- [54] S Khan, Mariya Amin Qurieshi, Inaamul Haq, Sabhiya Majid, Javid Ahmad, Taha Ayub, Anjum Bashir Fazili, Ashfaq Ahmad Bhat, Abdul Majeed Ganai, Yasmeen Jan, et al. Results of a population-based survey to estimate the seroprevalence of SARS-CoV-2 specific IgG antibodies in Kashmir, India, seven months after the appearance of the first COVID-19 case. 2021.
- [55] Dmitry Kobak. Excess mortality reveals Covid's true toll in Russia. *Significance*, 18(1):16, 2021.
- [56] John Kruschke. *Doing Bayesian data analysis: A tutorial with R, JAGS, and Stan*. Academic Press, 2014.
- [57] Matthias Kümmerer, Philipp Berens, and Jakob Macke. A simple Bayesian analysis of the infection fatality rate in Gangelt, and an uncertainty aware extrapolation to infection-counts in Germany. <https://matthias-k.github.io/BayesianHeinsberg.html>, 2020.
- [58] Paul C Lambert, Alex J Sutton, Paul R Burton, Keith R Abrams, and David R Jones. How vague is vague? A simulation study of the impact of the use of vague prior distributions in mcmc using winbugs. *Statistics in Medicine*, 24(15):2401–2428, 2005.

- [59] David A Leon, Vladimir M Shkolnikov, Liam Smeeth, Per Magnus, Markéta Pechholdová, and Christopher I Jarvis. COVID-19: a need for real-time monitoring of weekly excess deaths. *The Lancet*, 395(10234):E81, 2020.
- [60] Andrew T Levin, William P Hanage, Nana Owusu-Boaitey, Kensington B Cochran, Seamus P Walsh, and Gideon Meyerowitz-Katz. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. *European Journal of Epidemiology*, pages 1–16, 2020.
- [61] Zhongjie Li, Xuhua Guan, Naiying Mao, Huiming Luo, Ying Qin, Na He, Zhen Zhu, Jianxing Yu, Yu Li, Jianhua Liu, et al. Antibody seroprevalence in the epicenter wuhan, hubei, and six selected provinces after containment of the first epidemic wave of covid-19 in china. *The Lancet Regional Health-Western Pacific*, 8:100094, 2021.
- [62] Ruijie Ling, Yihan Yu, Jiayu He, Jixian Zhang, Sha Xu, Renrong Sun, Tao Li, Hong-Long Ji, and Huan-Qiang Wang. Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China. *China (6/15/2020)*, 2020.
- [63] Natalie M Linton, Tetsuro Kobayashi, Yichi Yang, Katsuma Hayashi, Andrei R Akhmetzhanov, Sung-mok Jung, Baoyin Yuan, Ryo Kinoshita, and Hiroshi Nishiura. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data. *Journal of Clinical Medicine*, 9(2):538, 2020.
- [64] Marc Lipsitch. First Opinion: We know enough now to act decisively against COVID-19. social distancing is a good place to start. STAT, <https://tinyurl.com/yx4gf9mr>, 2020.
- [65] Jiangmei Liu, Lan Zhang, Yaqiong Yan, Yuchang Zhou, Peng Yin, Jinlei Qi, Lijun Wang, Jingju Pan, Jinling You, Jing Yang, et al. Excess mortality in Wuhan city and other parts of china during the three months of the COVID-19 outbreak: findings from nationwide mortality registries. *The BMJ*, 372, 2021.
- [66] Mahajan et al. SARS-CoV-2 infection hospitalization rate and infection fatality rate among the non-congregate population in Connecticut. *The American Journal of Medicine*, 2021.
- [67] Mahajan et al. Seroprevalence of SARS-CoV-2-specific IgG antibodies among adults living in Connecticut: Post-infection prevalence (pip) study. *The American Journal of Medicine*, 134(4):526–534, 2021.
- [68] Hussaini Majiya, Mohammed Aliyu-Paiko, Vincent Tochukwu Balogu, Dickson Achimugu Musa, Ibrahim Maikudi Salihu, Abdullahi Abubakar Kawu, Ishaq Yakubu Bashir, Aishat Ra-

biu Sani, John Baba, Amina Tako Muhammad, et al. Seroprevalence of COVID-19 in Niger State. medRxiv, 2020.

- [69] Anup Malani, Daksha Shah, Gagandeep Kang, Gayatri Nair Lobo, Jayanthi Shastri, Manoj Mohanan, Rajesh Jain, Sachee Agrawal, Sandeep Juneja, Sofia Imad, et al. Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India. *The Lancet Global Health*, 9 (2):e110–e111, 2021.
- [70] Valerio Marra and Miguel Quartin. A Bayesian estimate of the COVID-19 infection fatality rate in Brazil based on a random seroprevalence survey. *International Journal of Infectious Diseases*, 2021. doi[:https://doi.org/10.1016/j.ijid.2021.08.016.](https://doi.org/https://doi.org/10.1016/j.ijid.2021.08.016)
- [71] Colleen C McLaughlin, Margaret K Doll, Kathryn T Morrison, William L McLaughlin, Terry O'Connor, Anton M Sholukh, Emily L Bossard, Khamsone Phasouk, Emily S Ford, Kurt Diem, et al. High community SARS-CoV-2 antibody seroprevalence in a ski resort community, Blaine County, Idaho, US. preliminary results. medRxiv, 2020.
- [72] Roberto Melotti, Federica Scaggiante, Michela Falciani, Christian X Weichenberger, Luisa Foco, Stefano Lombardo, Alessandro De Grandi, Dorothee von Laer, Angelika Mahlknecht, Peter P Pramstaller, et al. Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena Valley. *medRxiv*, 2021.
- [73] Gideon Meyerowitz-Katz and Lea Merone. A systematic review and metaanalysis of published research data on COVID-19 infection-fatality rates. *International Journal of Infectious Diseases*, 101:138–148, 2020. ISSN 1201-9712. doi[:https://doi.org/10.1016/j.ijid.2020.09.1464.](https://doi.org/https://doi.org/10.1016/j.ijid.2020.09.1464)
- [74] MoHoI Ministry of Health of Israel. National sero-epidemiological coverage for 19 c. [https://www.gov.il/BlobFolder/reports/de-covid19-28062020-17092020/](https://www.gov.il/BlobFolder/reports/de-covid19-28062020-17092020/he/files_publications_corona_DE-covid19.pdf) [he/files_publications_corona_DE-covid19.pdf](https://www.gov.il/BlobFolder/reports/de-covid19-28062020-17092020/he/files_publications_corona_DE-covid19.pdf), 2020.
- [75] Peter Morfeld, Barbara Timmermann, J Valerie Groß, Philip Lewis, Pierluigi Cocco, and ´ Thomas C Erren. COVID-19: Heterogeneous excess mortality and "burden of disease" in Germany and Italy and their states and regions, January–June 2020. *Frontiers in Public Health*, 9:477, 2021.
- [76] Bhramar Mukherjee, Soumik Purkayashtha, Ritoban Kundu, and Ritwik Bhaduri. Estimating the infection fatality rate from SARS-CoV-2 in India. Available at SSRN 3798552, 2021.
- [77] Zachary Munn, Sandeep Moola, Karolina Lisy, Dagmara Riitano, and Catalin Tufanaru. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *International Journal of Evidence-Based Healthcare*, 13(3):147–153, 2015.

- [78] Manoj V Murhekar, Tarun Bhatnagar, Sriram Selvaraju, V Saravanakumar, Jeromie Wesley Vivian Thangaraj, Naman Shah, Muthusamy Santhosh Kumar, Kiran Rade, R Sabarinathan, Smita Asthana, et al. SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. *The Lancet Global Health*, 9(3):e257–e266, 2021.
- [79] Murhekar et al. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. *Indian Journal of Medical Research*, 152(1):48, 2020.
- [80] Murhekar et al. SARS-CoV-2 antibody prevalence in India: Findings from the second nationwide household serosurvey, August-September 2020. *The Lancet Global Health*, 9(3): E257–E266, 2020.
- [81] Vivek Naranbhai, Christina C Chang, Wilfredo F Garcia Beltran, Tyler E Miller, Michael G Astudillo, Julian A Villalba, Diane Yang, Jeffrey Gelfand, Bradley E Bernstein, Jared Feldman, et al. High seroprevalence of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts. *The Journal of Infectious Diseases*, 222(12):1955–1959, 2020.
- [82] Nobutoshi Nawa, Jin Kuramochi, Shiro Sonoda, Yui Yamaoka, Yoko Nukui, Yasunari Miyazaki, and Takeo Fujiwara. Seroprevalence of sARS-CoV-2 IgG antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (u-corona): a household-and population-based study. *medRxiv*, 2020.
- [83] Muhammad Imran Nisar, MBBS Nadia Ansari, and Farah Khalid. Serial population-based sero-surveys for COVID-19 in low and high transmission. *medRxiv*, 2020.
- [84] Megan O'Driscoll, Gabriel Ribeiro Dos Santos, Lin Wang, Derek AT Cummings, Andrew S Azman, Juliette Paireau, Arnaud Fontanet, Simon Cauchemez, and Henrik Salje. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*, pages 1–6, 2020.
- [85] Office of National Statistics. Coronavirus (COVID-19) infection survey: England. [https:](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata) [// www. ons. gov. uk/ peoplepopulationandcommunity/ healthandsocialcare/](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata) [conditionsanddiseases/ datasets/ coronaviruscovid19infectionsurveydata](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata) , 2020.
- [86] Gabriele Pagani, Andrea Giacomelli, Federico Conti, Dario Bernacchia, Rossana Rondanin, Andrea Prina, Vittore Scolari, Arianna Rizzo, Martina Beltrami, Camilla Caimi, et al. Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d'Adda, Italy. *PloS one*, 16(2):e0246513, 2021.
- [87] Sen Pei, Teresa K Yamana, Sasikiran Kandula, Marta Galanti, and Jeffrey Shaman. Overall burden and characteristics of COVID-19 in the United States during 2020. *medRxiv*, 2021.

- [88] Michael J Peluso, Saki Takahashi, Jill Hakim, J Daniel Kelly, Leonel Torres, Nikita S Iyer, Keirstinne Turcios, Owen Janson, Sadie E Munter, Cassandra Thanh, et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. *medRxiv*, 2021.
- [89] Mayte Perez-Olmeda, Jose Maria Saugar, Aurora Fernández-García, Beatriz Perez-Gomez, Marina Pollan-Santamaria, Ana Avellon, Roberto Pastor-Barriuso, Nerea Fernandez-de ´ Larrea, Mariano Martín, Israel Cruz, et al. Evolution of antibodies against SARS-CoV-2 over seven months: experience of the nationwide seroprevalence ENE-COVID study in Spain. *medRxiv*, 2021.
- [90] Maria Skaalum Petersen, Marin Strøm, Debes Hammershaimb Christiansen, Jógvan Páll Fjallsbak, Eina Hansen Eliasen, Malan Johansen, Anna Sofía Veyhe, Marnar Frídhheim Kristiansen, Shahin Gaini, Lars Fodgaard Møller, et al. Seroprevalence of SARS-CoV-2– specific antibodies, Faroe Islands. *Emerging Infectious Diseases*, 26(11):2760, 2020.
- [91] Patrick Pietzonka, Erik Brorson, William Bankes, Michael E Cates, Robert L Jack, and Ronojoy Adhikari. Bayesian inference across multiple models suggests a strong increase in lethality of COVID-19 in late 2020 in the UK. medRxiv, 2021.
- [92] Marina Pollán, Beatriz Pérez-Gómez, Roberto Pastor-Barriuso, Jesús Oteo, Miguel A Hernán, Mayte Pérez-Olmeda, Jose L Sanmartín, Aurora Fernández-García, Israel Cruz, Nerea Fernández de Larrea, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *The Lancet*, 396(10250):535–544, 2020.
- [93] Hossein Poustchi, Maryam Darvishian, Zahra Mohammadi, Amaneh Shayanrad, Alireza Delavari, Ayad Bahadorimonfared, Saeid Eslami, Shaghayegh Haghjooy Javanmard, Ebrahim Shakiba, Mohammad Hossein Somi, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in iran: a populationbased cross-sectional study. *The Lancet Infectious Diseases*, 21(4):473–481, 2021.
- [94] Priyanka Pulla. What counts as a COVID-19 death? *The BMJ*, 370, 2020.
- [95] Soumik Purkayastha, Ritoban Kundu, Ritwik Bhaduri, Daniel Barker, Michael Kleinsasser, Debashree Ray, and Bhramar Mukherjee. Estimating the wave 1 and wave 2 infection fatality rates from SARS-CoV-2 in India. *medRxiv*, 2021.
- [96] Nouar Qutob, Faisal Awartani, Zaidoun Salah, Mohammad Asia, Imad Abu Khader, Khaled Herzallah, Nadeen Balqis, and Husam Sallam. Seroprevalence of SARS-CoV-2 in the West Bank region of Palestine: a cross-sectional seroepidemiological study. *BMJ open*, 11(2): e044552, 2021.

- [97] Katja Radon, Elmar Saathoff, Michael Pritsch, Jessica Michelle Guggenbuehl Noller, Inge Kroidl, Laura Olbrich, Verena Thiel, Maximilian Diefenbach, Friedrich Riess, Felix Forster, et al. Protocol of a population-based prospective COVID-19 cohort study Munich, Germany (koco19). *medRxiv*, 2020.
- [98] Sudarshan Ramaswamy, Aditya Athotra, PK Kasar, Rajesh Tiwari, Shashi Prabha Tomar, Ratnesh Kuraria, Arvind Rai, Meera Dhuria, Arti Bahl, Anil Digambar Patil, et al. Crosssectional study on sero-prevalence of SARS-CoV-2 infection in Jabalpur, Madhya Pradesh, India. *Journal of Communicable Diseases (E-ISSN: 2581-351X & P-ISSN: 0019-5138)*, 53 (1):82–88, 2021.
- [99] Shay Reicher, Ronit Ratzon, Shay Ben-Sahar, Sharon Hermoni-Alon, David Mossinson, Yotam Shenhar, Michael Friger, Yaniv Lustig, Sharon Alroy-Preis, Emilia Anis, et al. Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel. *European Journal of Epidemiology*, pages 1–8, 2021.
- [100] Mary F Reyes-Vega, M Gabriela Soto-Cabezas, Fany Cárdenas, Kevin S Martel, Andree Valle, Juan Valverde, Margot Vidal-Anzardo, María Elena Falcón, César V Munayco, Peru COVID-19 Working Group, et al. SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an lmic megacity: A population-based seroepidemiological survey in Lima, Peru. *EClinicalMedicine*, 34:100801, 2021.
- [101] Aude Richard, Ania Wisniak, Javier Perez-Saez, Henri Garrison-Desany, Dusan Petrovic, Giovanni Piumatti, Helene Baysson, Attilio Picazio, Francesco Pennacchio, David De Ridder, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study. *medRxiv*, 2020.
- [102] Tim Riffe, A Acosta, and Virginia Zarulli. COVerAGE-DB: A global demographic database of COVID-19 cases and deaths. *International Journal of Epidemiology*, 2021.
- [103] Eli S Rosenberg, James M Tesoriero, Elizabeth M Rosenthal, Rakkoo Chung, Meredith A Barranco, Linda M Styer, Monica M Parker, Shu-Yin John Leung, Johanne E Morne, Danielle Greene, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. *Annals of Epidemiology*, 48:23–29, 2020.
- [104] Cristina Royo-Cebrecos, David Vilanova, Joel López, Vanesa Arroyo, Marc Pons, Guillem Francisco, Mireia G Carrasco, Josep M Piqué, Sergi Sanz, Carlota Dobaño, et al. Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra. *The Lancet Regional Health-Europe*, 5:100119, 2021.
- [105] Matthew Samore, Adam Looney, Brian Orleans, Tom Greene, Nathan Seegert, Julio C Delgado, Angela Presson, Chong Zhang, Jian Ying, Yue Zhang, et al. SARS-CoV-2 sero-

prevalence and detection fraction in Utah urban populations from a probability-based sample. *medRxiv*, 2020.

- [106] Claudia Santos-Hovener, Hannelore K Neuhauser, Angelika Schaffrath Rosario, Markus ¨ Busch, Martin Schlaud, Robert Hoffmann, Antje Goßwald, Carmen Koschollek, Jens Hoebel, ¨ Jennifer Allen, et al. Serology-and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (comolo study), Germany, May to June 2020. *Eurosurveillance*, 25(47):2001752, 2020.
- [107] Sriram Selvaraju, Muthusamy Santhosh Kumar, Jeromie Wesley Vivian Thangaraj, Tarun Bhatnagar, Velusamy Saravanakumar, Chethrapilly Purushothaman Girish Kumar, Krithikaa Sekar, Ezhilarasan Ilayaperumal, Ramasamy Sabarinathan, Murugesan Jagadeesan, et al. Population-based serosurvey for severe acute respiratory syndrome coronavirus 2 transmission, chennai, india. *Emerging Infectious Diseases*, 27(2):586, 2021.
- [108] Edgardo R Sepulveda, Nathan M Stall, and Samir K Sinha. A comparison of COVID-19 mortality rates among long-term care residents in 12 OECD countries. *Journal of the American Medical Directors Association*, 21(11):1572–1574, 2020.
- [109] Maryam Shakiba, Seyed Saeed Hashemi Nazari, Fardin Mehrabian, Seyed Mahmoud Rezvani, Zahra Ghasempour, and Abtin Heidarzadeh. Seroprevalence of COVID-19 virus infection in Guilan province, Iran. *medRxiv*, 2020.
- [110] Nandini Sharma, Pragya Sharma, Saurav Basu, Sonal Saxena, Rohit Chawla, Kumar Dushyant, Nutan Mundeja, Z SK Marak, Sanjay Singh, Gautam Kumar Singh, et al. The seroprevalence and trends of SARS-CoV-2 in Delhi, India: A repeated population-based seroepidemiological study. medRxiv, 2020.
- [111] Donald Sharpe. Of apples and oranges, file drawers and garbage: Why validity issues in meta-analysis will not go away. *Clinical Psychology Review*, 17(8):881–901, 1997.
- [112] Bonnie E Shook-Sa, Ross M Boyce, and Allison E Aiello. Estimation without representation: early severe acute respiratory syndrome coronavirus 2 seroprevalence studies and the path forward. *The Journal of Infectious Diseases*, 222(7):1086–1089, 2020.
- [113] Mariângela F Silveira, Aluísio JD Barros, Bernardo L Horta, Lúcia C Pellanda, Gabriel D Victora, Odir A Dellagostin, Claudio J Struchiner, Marcelo N Burattini, Andreia RM Valim, ´ Evelise M Berlezi, et al. Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil. *Nature Medicine*, 26(8):1196–1199, 2020.
- [114] Mariangela Freitas Silveira, Marilia Mesenburg, Odir Antonio Dellagostin, Natasha R Oliveira, Mara Andrade Colares Maia, Francisco Denis Souza Santos, Andre M Vale, Aluisio

Barros, Luis Paulo Vidaletti, Fernando C Barros, et al. Time-dependent decay of detectable antibodies against SARS-CoV-2: A comparison of elisa with two batches of a lateral-flow test. *The Brazilian Journal of Infectious Diseases*, 101601, 2021.

- [115] Chantal J Snoeck, Michel Vaillant, Tamir Abdelrahman, Venkata P Satagopam, Jonathan D Turner, Katy Beaumont, Clarissa PC Gomes, Joelle Veronique Fritz, Valerie E Schroder, ¨ Anne Kaysen, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. *medRxiv*, 2020.
- [116] Neeraj Sood, Paul Simon, Peggy Ebner, Daniel Eichner, Jeffrey Reynolds, Eran Bendavid, and Jay Bhattacharya. Seroprevalence of SARS-CoV-2–specific antibodies among adults in Los Angeles County, California, on april 10-11, 2020. *JAMA*, 323(23):2425–2427, 2020.
- [117] Nicola A Spiers. Rapid response: Comparing REACT with the ONS Infection Survey. *The BMJ*, 2020. URL <https://www.bmj.com/content/371/bmj.m3850/rr>.
- [118] Statistics Jersey. SARS-CoV-2: prevalence of antibodies in Jersey (community survey round 2). *https://tinyurl.com/6htjn3af*, 2020.
- [119] Statistics Jersey. SARS-CoV-2: prevalence of antibodies in Jersey (community survey round 3). *https://tinyurl.com/hxd8sadb*, 2020.
- [120] Paola Stefanelli, Antonino Bella, Giorgio Fedele, Serena Pancheri, Pasqualina Leone, Paola Vacca, Arianna Neri, Anna Carannante, Cecilia Fazio, Eleonora Benedetti, et al. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study. *Clinical Microbiology and Infection*, 27(4): 633–e1, 2021.
- [121] Hendrik Streeck, Bianca Schulte, Beate M. Kümmerer, Enrico Richter, Tobias Höller, Christine Fuhrmann, Eva Bartok, Ramona Dolscheid-Pommerich, Moritz Berger, Lukas Wessendorf, Monika Eschbach-Bludau, Angelika Kellings, Astrid Schwaiger, Martin Coenen, Per Hoffmann, Birgit Stoffel-Wagner, Markus M. Nöthen, Anna M. Eis-Hübinger, Martin Exner, Ricarda Maria Schmithausen, Matthias Schmid, and Gunther Hartmann. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. *Nature Communications*, 11(1):5829, 2020. doi[:10.1038/s41467-020-19509-y.](https://doi.org/10.1038/s41467-020-19509-y)
- [122] Silvia Stringhini, Ania Wisniak, Giovanni Piumatti, Andrew S Azman, Stephen A Lauer, Hélène Baysson, David De Ridder, Dusan Petrovic, Stephanie Schrempft, Kailing Marcus, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (serocovpop): a population-based study. *The Lancet*, 396(10247):313–319, 2020.
- [123] Silvia Stringhini, María-Eugenia Zaballa, Javier Perez-Saez, Nick Pullen, Carlos de Mestral, Attilio Picazio, Francesco Pennacchio, Ania Wisniak, Aude Richard, Helene Baysson, et al.

Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak. *The Lancet. Infectious Diseases*, 21(5):600–601, 2021.

- [124] Patrick Sullivan, Aaron Siegler, Kayoko Shioda, Eric W Hall, Heather Bradley, Travis H Sanchez, Nicole Luisi, Mariah Valentine-Graves, Kristin N Nelson, Mansour Fahimi, et al. SARS-CoV-2 cumulative incidence, United States, August-December 2020. *Clinical Infectious Diseases*, page ciab626, 2021.
- [125] Beatriz H Tess, Celso FH Granato, Maria CGP Alves, Maria C Pintao, Edgar Rizzatti, Marcia C Nunes, and Fernando C Reinach. SARS-CoV-2 seroprevalence in the municipality of Sao Paulo, Brazil, ten weeks after the first reported case. ˜ *medRxiv*, 2020.
- [126] The Economist. Covid-19 deaths in wuhan seem far higher than the official count. [https://www.economist.com/graphic-detail/2021/05/30/](https://www.economist.com/graphic-detail/2021/05/30/covid-19-deaths-in-wuhan-seem-far-higher-than-the-official-count) [covid-19-deaths-in-wuhan-seem-far-higher-than-the-official-count](https://www.economist.com/graphic-detail/2021/05/30/covid-19-deaths-in-wuhan-seem-far-higher-than-the-official-count), 2021.
- [127] F Truc and Gianpiero Gervino. The effects of physical distancing and lockdown to restrain SARS-CoV-2 outbreak in the Italian municipality of Cogne. *Available at SSRN 3848514*, 2021.
- [128] Agne Ulyte, Thomas Radtke, Irene A Abela, Sarah R Haile, Christoph Berger, Michael Huber, Merle Schanz, Magdalena Schwarzmueller, Alexandra Trkola, Jan Fehr, et al. Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools. *The BMJ*, 372, 2021.
- [129] Thomas R Vetter and Patrick Schober. Agreement analysis: what he said, she said versus you said. *Anesthesia & Analgesia*, 126(6):2123–2128, 2018.
- [130] Eric R A Vos, Gerco den Hartog, Rutger M Schepp, Patricia Kaaijk, Jeffrey van Vliet, Kina Helm, Gaby Smits, Alienke Wijmenga-Monsuur, Janneke D M Verberk, Michiel van Boven, Rob S van Binnendijk, Hester E de Melker, Liesbeth Mollema, and Fiona R M van der Klis. Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the netherlands during the first epidemic wave. *Journal of Epidemiology & Community Health*, 75(6):489–495, 2021. ISSN 0143-005X. doi[:10.1136/jech-2020-215678.](https://doi.org/10.1136/jech-2020-215678)
- [131] Rochelle P Walensky, Henry T Walke, and Anthony S Fauci. SARS-CoV-2 variants of concern in the United States—Challenges and opportunities. *JAMA*, 325(11):1037–1038, 2021.
- [132] Xiaoli Wang, Wenjing Gao, Shujuan Cui, Yi Zhang, Ke Zheng, Ji Ke, Jun Lv, Canqing Yu, Dianjianyi Sun, Quanyi Wang, et al. A population-based seroprevalence survey of severe acute respiratory syndrome coronavirus 2 infection in Beijing, China. *medRxiv*, 2020.

- [133] Helen Ward, Graham Cooke, Christina J Atchison, Matthew Whitaker, Joshua Elliott, Maya Moshe, Jonathan C Brown, Barney Flower, Anna Daunt, Kylie EC Ainslie, et al. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. *medRxiv*, 2020.
- [134] Josiane Warszawski, Nathalie Bajos, Laurence Meyer, et al. In May 2020, 4.5% of the population of metropolitan France had developed antibodies against SARS-CoV-2. [https://drees.solidarites-sante.gouv.fr/sites/default/files/2021-01/](https://drees.solidarites-sante.gouv.fr/sites/default/files/2021-01/er1167-en.pdf) [er1167-en.pdf](https://drees.solidarites-sante.gouv.fr/sites/default/files/2021-01/er1167-en.pdf), 2020.
- [135] Elizabeth J Williamson, Alex J Walker, Krishnan Bhaskaran, Seb Bacon, Chris Bates, Caroline E Morton, Helen J Curtis, Amir Mehrkar, David Evans, Peter Inglesby, et al. Factors associated with covid-19-related death using opensafely. *Nature*, 584(7821):430–436, 2020.
- [136] Joseph T Wu, Kathy Leung, Mary Bushman, Nishant Kishore, Rene Niehus, Pablo M de Salazar, Benjamin J Cowling, Marc Lipsitch, and Gabriel M Leung. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. *Nature Medicine*, 26(4):506–510, 2020.
- [137] Takashi Yoshiyama, Yasuki Saito, Kunitsugu Masuda, Yoshiko Nakanishi, Yasutoshi Kido, Kazuhiro Uchimura, Satoshi Mitarai, Tadaki Suzuki, Yu Nakagama, Hiroshi Kubota, et al. Prevalence of sARS-CoV-2–specific antibodies, japan, june 2020. *Emerging Infectious Diseases*, 27(2):628, 2021.
- [138] Petra Zimmermann and Nigel Curtis. Why is COVID-19 less severe in children? a review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. *Archives of Disease in Childhood*, 106(5):429–439, 2021.

7 Supplementary Material

7.1 Excluded studies - Chen et al.-based analysis

Figure [1](#page-7-0) shows a flowchart of the literature search and Table [6](#page-32-0) lists all the excluded studies. Among the 38 articles obtained from the Chen et al. review, four studies represented results from different phases of the same study. For each of these we considered only the data from the earliest phase of the study. Stringhini et al. [\[122\]](#page-29-1) and Richard et al. [\[101\]](#page-27-1) are two publications that report the earlier and later phases, respectively, of the same study of Geneva, Switzerland. We considered only data from the earlier phase as reported in Stringhini et al. [\[122\]](#page-29-1). Murhekar et al. [\[79\]](#page-25-3) and Murhekar et al. [\[80\]](#page-25-4) are two publications that report the earlier and later phases, respectively, of the same study in India. We considered only data from the first phase as reported in [\[79\]](#page-25-3).

Note that, while similar in many ways, Ward et al. [\[133\]](#page-31-0) and Office of National Statistics [\[85\]](#page-25-5) are two different large-sample studies. The Ward et al. [\[133\]](#page-31-0) study is based on the "REACT-2" survey which is led by Imperial College London, while the Office of National Statistics [\[85\]](#page-25-5) study is based on the "Coronavirus (COVID-19) Infection Survey" which is conducted by a partnership between the University of Oxford, University of Manchester, Public Health England and Wellcome Trust. Spiers [\[117\]](#page-29-2) discusses the differences between the two surveys.

We excluded eight studies that used "non-probability" or "convenience" sampling methods (e.g, studies in which participants were recruited using social media, or recruited in shopping centers). Specifically, we excluded: (1) McLaughlin et al. [\[71\]](#page-24-4) who sampled individuals from a list of volunteers (Arora et al. [\[6\]](#page-17-0) classifies the sampling method for this study as "self-referral"); (2) Rosenberg et al. [\[103\]](#page-27-2) who sampled individuals at grocery stores ("convenience" [\[6\]](#page-17-0)); (3) Appa et al. [\[5\]](#page-17-3) who recruited volunteers with support from Bolinas community leaders ("self-referral" [\[6\]](#page-17-0)); (4) Bendavid et al. [\[14\]](#page-18-5) who recruited participants by placing targeted advertisements on Facebook ("stratified non-probability" [\[6\]](#page-17-0)); (5) Gudbjartsson et al. [\[40\]](#page-21-6) ("convenience" [\[6\]](#page-17-0)); (6) Borges et al. [\[20\]](#page-19-5) ("convenience" [\[6\]](#page-17-0)); (7) Ling et al. [\[62\]](#page-23-6) ("self-referral" [6]); and (8) Naranbhai et al. [\[81\]](#page-25-6) ("convenience" [\[6\]](#page-17-0)). Due to new information about the sensitivity of the Wondfo antibody tests (Silveira et al. [\[114\]](#page-28-3): "Our findings cast serious doubts about the use of this brand of rapid tests for epidemiological studies."), we excluded the Hallal et al. [\[41\]](#page-21-7) Brazil study (but do see: Marra and Quartin [\[70\]](#page-24-5)). One study (Malani et al. [\[69\]](#page-24-6)) was excluded due to a narrowly defined target population.

Two additional studies were not included because the articles failed to report 95% uncertainty intervals for the estimated infection rate in the target population [\[68,](#page-23-7) [132\]](#page-30-4) and five additional studies were not included due to unavailable reliable mortality data for the specific target populations [\[1,](#page-17-1) [83,](#page-25-1) [93,](#page-26-6) [125,](#page-30-5) [109\]](#page-28-4).

Table 6: List of excluded studies and reason for exclusion for the Chen et al. - based analysis.

7.2 Excluded studies - Serotracker-based analysis

Figure [2](#page-8-0) shows a flowchart of the literature search and Table [7](#page-35-0) lists all the excluded studies. Among the 45 articles obtained from the Serotracker review, six studies represented results from different phases of the same study. For each of these we considered only the data from the earliest phase of the study. For instance, Murhekar et al. [\[79\]](#page-25-3) and Murhekar et al. [\[80\]](#page-25-4) report the results from an earlier and a later phase of the same study in India. We only include Murhekar et al. [\[79\]](#page-25-3) for our analysis. We excluded one additional study that used "convenience" sampling methods [\[120\]](#page-29-3) and two studies that used the Wondfo antibody test [\[61,](#page-23-8) [113\]](#page-28-5) (without adequate adjustment given the recent information about the sensitivity of the Wondfo test Silveira et al. [\[114\]](#page-28-3)). We excluded two additional studies that had a narrowly defined target population[\[8,](#page-18-6) [128\]](#page-30-6).

One additional study was not included because the article failed to report a 95% uncertainty interval for the estimated infection rate in the target population (Truc and Gervino [\[127\]](#page-30-7) focused on estimating the longitudinal changes in antibodies levels rather than the prevalence rate in Cogne, Italy.). Note that the "Andorra" study [\[38\]](#page-21-8) also failed to report a 95% uncertainty interval for the estimated infection rate in the target population. However, we chose to exceptionally include the study due to the fact that it represents one of the largest seroprevalence studies conducted: a total of 70,494 inhabitants (90.9% of the population of Andorra) participated in the study. In their published article Royo-Cebrecos et al. [\[104\]](#page-27-3) explain that 95% confidence intervals are not provided because such intervals "would be extremely narrow and potentially misleading given that they do not account for the potential bias that non-participating individuals could cause on our central seroprevalence estimate." We therefore defined, in order to be very cautious, a very wide (yet entirely arbitrary) 95% confidence interval of [10.5%, 11.5%] around the 11.0% point estimate. Eight additional studies were not included due to unavailable reliable mortality data for the specific target populations.

Table 7: List of excluded studies and reason for exclusion for the Serotracker-based analysis.

7.3 Details on mortality and covariate data

• For Álvarez-Antonio et al. [\[3\]](#page-17-4) ("Iquitos, Peru") (see also Álvarez-Antonio et al. [\[2\]](#page-17-5)), we used official (post-audit) numbers from the Peru Ministry of Health (MINSA) (see [https://www.datosabiertos.gob.pe/dataset/](https://www.datosabiertos.gob.pe/dataset/fallecidos-por-covid-19-ministerio-de-salud-minsa/resource/4b7636f3-5f0c-4404-8526) [fallecidos-por-covid-19-ministerio-de-salud-minsa/resource/](https://www.datosabiertos.gob.pe/dataset/fallecidos-por-covid-19-ministerio-de-salud-minsa/resource/4b7636f3-5f0c-4404-8526) [4b7636f3-5f0c-4404-8526](https://www.datosabiertos.gob.pe/dataset/fallecidos-por-covid-19-ministerio-de-salud-minsa/resource/4b7636f3-5f0c-4404-8526)) for mortality numbers. We included deaths recorded for 4 districts ("SAN JUAN BAUTISTA", "BELEN", "PUNCHANA", and "IQUITOS") in the Loreto department. Note that recording the accurate number of deaths is perhaps particularly challenging in Iquitos; see Fraser [\[33\]](#page-20-8). In order to acknowledge that there is

substantial uncertainty in the post-audit mortality numbers, we widened the interval by lowering the lower bound by 10% and increasing the upper bound by 10%. Data for the proportion aged over 65 is from a 2004 World Health Organization report (see [https:](https://www.who.int/ageing/projects/intra/phase_two/alc_intra2_cp_peru.pdf) [//www.who.int/ageing/projects/intra/phase_two/alc_intra2_cp_peru.pdf](https://www.who.int/ageing/projects/intra/phase_two/alc_intra2_cp_peru.pdf); accessed August 2, 2021). GDP data is from the "USD per head, current prices, current PPP" value listed by the Organisation for Economic Co-operation and Development's Gross Domestic Product, Large regions TL2 database ("OECD database"; see <https://stats.oecd.org/>, accessed August 10, 2021) for the Loreto region (PE16). Population data is from the published article [\[2\]](#page-17-5).

- For Warszawski et al. [\[134\]](#page-31-2) ("Metropolitan, France"), we obtained mortality data from the French government COVID-19 dashboard (see [https://dashboard.](https://dashboard.covid19.data.gouv.fr/vue-d-ensemble?location=FRA) [covid19.data.gouv.fr/vue-d-ensemble?location=FRA](https://dashboard.covid19.data.gouv.fr/vue-d-ensemble?location=FRA); accessed on August 4, 2021), summing up the cumulative deaths for the 13 regions of Metropolitain France (i.e., European France). Note that this death total does not include deaths that occurred in long term care facilities (i.e., those listed separately under "EHPAD et EMS"). Data for the proportion aged over 65 is for France from 2019 as listed by World Bank's World Development Indicators (WDI) data ([https:](https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS?locations=FR) [//data.worldbank.org/indicator/SP.POP.65UP.TO.ZS?locations=FR](https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS?locations=FR); accessed August 4, 2021). GDP data is from the OECD database. Population data is from INSEE in report titled "Population totale par sexe et âge au 1er janvier 2020, France métropolitaine" (see <https://www.insee.fr/fr/statistiques/1892088?sommaire=1912926>; accessed August 4, 2021). We subtract 611,000 to account for those living in long term-care facilities (EHPAD) (see [https://www.lemonde.fr/societe/article/2020/12/02/](https://www.lemonde.fr/societe/article/2020/12/02/le-besoin-de-places-en-ehpad-va-devenir-massif-d-ici-a-2030_6061915_3224.html) [le-besoin-de-places-en-ehpad-va-devenir-massif-d-ici-a-2030_6061915_](https://www.lemonde.fr/societe/article/2020/12/02/le-besoin-de-places-en-ehpad-va-devenir-massif-d-ici-a-2030_6061915_3224.html) [3224.html](https://www.lemonde.fr/societe/article/2020/12/02/le-besoin-de-places-en-ehpad-va-devenir-massif-d-ici-a-2030_6061915_3224.html); accessed August 4, 2021) since the serostudy data specifically apply to "Individuals aged 15 years or above, residing in metropolitan France, excluding EHPADs, retirement homes and prisons."
- For Bajema et al. [\[9\]](#page-18-8) ("DeKalb and Fulton, GA, USA (2)"), we obtained the number of deaths for DeKalb, and Fulton counties from the county-level COVID-19 dataset curated by the New York Times available at: [github.com/nytimes/](github.com/nytimes/covid-19-data) [covid-19-data](github.com/nytimes/covid-19-data) (accessed on April 28, 2021). Data for the proportion aged over 65 is from [https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/](https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/blob/master/data/README.md) [blob/master/data/README.md](https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/blob/master/data/README.md) (accessed on April 29, 2021). GDP value is from value listed in the OECD database for the state of Georgia, USA (US13). Population is from the United States census (<https://www.census.gov/quickfacts/fultoncountygeorgia> and <https://www.census.gov/quickfacts/dekalbcountygeorgia> ; accessed July 28,

2021) (i.e., 759297 + 1063937). Note that both Bajema et al. [\[9\]](#page-18-8) and Biggs et al. [\[18\]](#page-19-6) report the results from the same seroprevalence study.

- For Barchuk et al. [\[11\]](#page-18-3) ("Saint Petersburg, Russia"), we used excess death numbers as reported by Kobak [\[55\]](#page-22-9). Russian official statistics appear to underestimate the true number of fatalities by a substantial factor [\[51\]](#page-22-3). Data for the proportion aged over 65 is from Barchuk et al. [\[11\]](#page-18-3) (see Table A3 "KOUZh-2018"). GDP value is from OECD database for the "Federal City of Saint Petersburg" (RU29) region. The population value is from https://en.wikipedia.org/wiki/Saint_Petersburg (accessed June 21, 2021)).
- For Biggs et al. [\[18\]](#page-19-6) ("DeKalb and Fulton, GA, USA (1)"), the number of deaths for DeKalb, and Fulton counties was obtained from the county-level COVID-19 dataset curated by the New York Times available at: [github.com/nytimes/](github.com/nytimes/covid-19-data) [covid-19-data](github.com/nytimes/covid-19-data) (accessed on April 28, 2021). Data for the proportion aged over 65 is from [https://github.com/JieYingWu/COVID-19_US_County-level_](https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/blob/master/data/README.md) [Summaries/blob/master/data/README.md](https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/blob/master/data/README.md) (accessed on April 29, 2021). Data for the proportion aged over 65 is from [https://github.com/JieYingWu/COVID-19_](https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/blob/master/data/README.md) [US_County-level_Summaries/blob/master/data/README.md](https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/blob/master/data/README.md) (accessed on April 29, 2021). GDP value is from value listed in the OECD database for the state of Georgia, USA (US13). Population is from the United States census ([https:](https://www.census.gov/quickfacts/fultoncountygeorgia) [//www.census.gov/quickfacts/fultoncountygeorgia](https://www.census.gov/quickfacts/fultoncountygeorgia) and [https://www.census.](https://www.census.gov/quickfacts/dekalbcountygeorgia) [gov/quickfacts/dekalbcountygeorgia](https://www.census.gov/quickfacts/dekalbcountygeorgia); accessed July 28, 2021) (i.e., 759297 + 1063937). Note that both Bajema et al. [\[9\]](#page-18-8) and Biggs et al. [\[18\]](#page-19-6) report the results from the same seroprevalence study.
- For Bruckner et al. [\[24\]](#page-19-7) ("Orange County, CA, USA"), we obtained number of cumulative deaths for Orange County from Orange County Public Works (as refer-enced by Bruckner et al. [\[24\]](#page-19-7)) at: [data-ocpw.opendata.arcgis.com/datasets/](data-ocpw.opendata.arcgis.com/datasets/2ec9342ffc814cf58161b1cca57365fd_0) [2ec9342ffc814cf58161b1cca57365fd_0](data-ocpw.opendata.arcgis.com/datasets/2ec9342ffc814cf58161b1cca57365fd_0) (accessed on April 28, 2021). Data for the proportion aged over 65 is from [https://github.com/JieYingWu/COVID-19_](https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/blob/master/data/README.md) [US_County-level_Summaries/blob/master/data/README.md](https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/blob/master/data/README.md) (accessed on April 29, 2021). GDP value is from value listed for the state of California, USA (US06) from the OECD database. Population value obtained from the United States census ([https:](https://www.census.gov/quickfacts/orangecountycalifornia) [//www.census.gov/quickfacts/orangecountycalifornia](https://www.census.gov/quickfacts/orangecountycalifornia); accessed June 27, 2021).
- For Carrat et al. [\[26\]](#page-19-8) ("Île-de-France, France"), we only consider Île-de-France phase of the study (see Supp. Table 1 in Carrat et al. [\[26\]](#page-19-8) for sampling dates). Data for the number of deaths for Île-de-France was obtained from the French government COVID-19 dashboard (see [https://dashboard.covid19.data.gouv.fr/](https://dashboard.covid19.data.gouv.fr/vue-d-ensemble?location=FRA) [vue-d-ensemble?location=FRA](https://dashboard.covid19.data.gouv.fr/vue-d-ensemble?location=FRA); accessed on August 4, 2021). Note that this death

> total does not include deaths that occurred in long term care facilities ("EHPAD et EMS"). Data for the proportion aged over 65 is from [https://contrevues.paris/](https://contrevues.paris/ile-de-france-comment-le-vieillissement-de-la-population-impacte-lhabitat/) [ile-de-france-comment-le-vieillissement-de-la-population-impacte-lhabitat/](https://contrevues.paris/ile-de-france-comment-le-vieillissement-de-la-population-impacte-lhabitat/) (accessed on April 29, 2021). GDP value is from value listed for ˆIle-de-France region (FR1) from OECD database. Population data from the Institut national de la statistique et des etudes economiques (INSEE) (see <https://www.insee.fr/fr/statistiques/5002478>; accessed July 29, 2021).

- For Chan et al. [\[27\]](#page-20-4) ("Rhode Island, USA"), we obtained mortality data from the Rhode Island Department of Health available at [https://](https://ri-department-of-health-covid-19-data-rihealth.hub.arcgis.com/) ri-department-of-health-covid-19-data-rihealth.hub.arcgis.com/ (accessed July 28, 2021). Note that Chan et al. [\[27\]](#page-20-4) state that: "As of May 31, Rhode Island had reported 827 cumulative lab-confirmed SARS- CoV-2–involved deaths; 78.5% of these deaths were associated with congregate care facilities. After exclusion of these deaths (and based on a 1.06 million state population), the estimated infection fatality rate corresponding to the unweighted seroprevalence of 2.1% was 7.7 per 1000 (95% CI = 3.9, 26.9); the infection fatality rate corresponding to the age-weighted seroprevalence of 2.9% was 5.6 per 1000 (95% CI = 2.6, 16.1)." This suggests that the appropriate number of deaths for the target population should not include those deaths "associated with congregate care facilities". As such we reduced the numbers for the deaths by 78.5% $(= 684 \times (1 - 0.785)$ and $= 877 \times (1 - 0.785)$). Data for the proportion aged over 65 is from the U.S. Department of Commerce <https://www.census.gov/quickfacts/RI> (accessed on June 21, 2021). GDP value is from value listed for the state of Rhode Island, USA (US44) in the OECD database. The population value is obtained from the United States census (<https://www.census.gov/quickfacts/RI>; accessed July 28, 2021).
- For Govern d'Andorra [\[38\]](#page-21-8) ("Andorra") (see also Royo-Cebrecos et al. [\[104\]](#page-27-3)), we obtained mortality numbers from the Government of Andorra ([https://www.](https://www.govern.ad/coronavirus) [govern.ad/coronavirus](https://www.govern.ad/coronavirus); accessed on June 28, 2021) as tabulated by Wikipedia (https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Andorra; accessed on June 28, 2021). Data for the proportion aged over 65 is from [https://www.](https://www.indexmundi.com/andorra/demographics_profile.html) [indexmundi.com/andorra/demographics_profile.html](https://www.indexmundi.com/andorra/demographics_profile.html) (accessed on June 28, 2021) and GDP data is from The World Factbook ([https://statisticstimes.com/economy/](https://statisticstimes.com/economy/countries-by-gdp-capita-ppp.php) [countries-by-gdp-capita-ppp.php](https://statisticstimes.com/economy/countries-by-gdp-capita-ppp.php); accessed on June 28, 2021)). The population number is as stated in the Royo-Cebrecos et al. [\[104\]](#page-27-3) which is the published article reporting on the study.
- For Kar et al. [\[50\]](#page-22-10) ("Puducherry District, India"), data for the number of deaths for Puducherry District was obtained from [https://covid19dashboard.py.gov.in/](https://covid19dashboard.py.gov.in/Reporting/District)

> [Reporting/District](https://covid19dashboard.py.gov.in/Reporting/District) (accessed on August 5, 2021). We multiplied the number recorded for 14 days after the end of the sampling window by a factor of 2.1 (based on the upper bound of Mukherjee et al. [\[76\]](#page-24-2)'s estimated underreporting factor for Puducherry) in order to account for potential underreporting. As such, our interval is relatively wide and reflects the uncertainty in the true number of deaths. Data for the proportion aged over 65 is from [http://statisticstimes.com/demographics/india/](http://statisticstimes.com/demographics/india/puducherry-population.php) [puducherry-population.php](http://statisticstimes.com/demographics/india/puducherry-population.php) (accessed on June 22, 2021). GDP value is from value listed for Puducherry (IN34) from OECD database. Population for Puducherry District from Kar et al. [\[50\]](#page-22-10) who note that: "Puducherry district, population ≈ 1.25 million, is located in southern India."

- For Khalagi et al. [\[52\]](#page-22-4) ("Iran"), Karlinsky and Kobak [\[51\]](#page-22-3) suggest that official mortality data for Iran is highly inaccurate and suggest that there have been approx. 58,092 excess deaths in Iran for the period until Sept. 21, 2020. This coincides with the estimate provided by [\[37\]](#page-20-9) of 58,900 (95% CI 46,900 - 69,500) for the period from December 22, 2019 to September 21, 2020. Excess mortality data is only available in quarterly format from Karlinsky and Kobak [\[51\]](#page-22-3). As such, it is not possible to obtain mortality data for the specific dates we require: 2020-08-17 and 2020-11-14. Official statistics for these dates are 19,804 and 41,034 (see https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Iran; accessed on June 28, 2021, which cites the Iranian Ministry of Health and Medical Education). Multiplying these numbers by Karlinsky and Kobak [\[51\]](#page-22-3)'s estimated undercount ratio of 2.4 gives: 47332 and 98071. (see [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852240/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852240/pdf/nihpp-2021.01.27.21250604v3.pdf) [pdf/nihpp-2021.01.27.21250604v3.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852240/pdf/nihpp-2021.01.27.21250604v3.pdf); accessed on June 28, 2021). Data for the population and the proportion of the population aged over 65 is from the World Bank World Development Indicators (WDI) data ([https://data.worldbank.org/indicator/](https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS?locations=IR) [SP.POP.65UP.TO.ZS?locations=IR](https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS?locations=IR); accessed on June 28, 2021). GDP value is also from the WDI data (see: <https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD> (last updated 2021-04-26)).
- For Mahajan et al. [\[67\]](#page-23-4) ("Connecticut, USA"), mortality data obtained from Wikipedia (https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Connecticut; accessed on July 22, 2021), who reference (<https://portal.ct.gov/Coronavirus>). Mortality numbers $(4,287 \text{ and } 4,450)$ are multiplied by 26.5% (i.e. by 1079/4071) due to the fact that approx. 26.5% of COVID-19 deaths in Connecticut occurred in the non-congregate population according to Mahajan et al. [\[66\]](#page-23-9). Data for the proportion aged over 65 is derived from Table 1 of Mahajan et al. [\[66\]](#page-23-9). GDP value is from value listed for the state of Connecticut, USA (US09) from the OECD database. Population value is obtained from [\[66\]](#page-23-9).

- For Malani et al. [\[69\]](#page-24-6) ("Tamil Nadu, India"), the population of Tamil-Nadu, India, was obtained from <https://www.indiacensus.net/states/tamil-nadu> (accessed July 27, 2021). Mortality data for the number of deaths for Tamil Nadu was obtained from the Tamil Nadu Government (see https://stopcorona.tn.gov.in/archive/; accessed June 24, 2021). We multiplied the number recorded for 14 days after the end of the sampling window of 11,909 by a factor of 2.5 (based on the upper bound of Mukherjee et al. [\[76\]](#page-24-2)'s estimated underreporting factor for Tamil Nadu). GDP value is from value listed for Tamil-Nadu (IN33) from the OECD database. Data for the proportion aged over 65 is from [https://statisticstimes.](https://statisticstimes.com/demographics/india/tamil-nadu-population.php) [com/demographics/india/tamil-nadu-population.php](https://statisticstimes.com/demographics/india/tamil-nadu-population.php) (accessed July 27, 2021).
- For Melotti et al. [\[72\]](#page-24-7) ("Gardena Valley, Italy"), we obtained data from the report "Study on the prevalence of Covid-19 in the Val Gardena - June 2020" (see: [https://astat.provincia.bz.it/it/news-pubblicazioni-info.asp?news_](https://astat.provincia.bz.it/it/news-pubblicazioni-info.asp?news_action=300&news_image_id=1074603) [action=300&news_image_id=1074603](https://astat.provincia.bz.it/it/news-pubblicazioni-info.asp?news_action=300&news_image_id=1074603); accessed July 27, 2021). In this report, it is noted that "the number of deaths from this disease in 17 people [...]". Stefano Lombardo (in a personal correspondence) notes that the source of this number is "AS-TAT, Bolzano" (listed under "statistics on deaths by cause") but this could not be verified. The study looks specifically at three municipalities (Ortisei, Santa Cristina, and Selva) and we have found age data from [https://www.citypopulation.de/en/](https://www.citypopulation.de/en/italy/trentinoaltoadige/bolzano/021089__selva_di_val_gardena/) [italy/trentinoaltoadige/bolzano/021089__selva_di_val_gardena/](https://www.citypopulation.de/en/italy/trentinoaltoadige/bolzano/021089__selva_di_val_gardena/) and [http:](http://italia.indettaglio.it/eng/trentinoaltoadige/ortisei.html) [//italia.indettaglio.it/eng/trentinoaltoadige/ortisei.html](http://italia.indettaglio.it/eng/trentinoaltoadige/ortisei.html) (accessed August 4, 2021). GDP value is from OECD database for the Province of Bolzano-Bozen (ITH1).
- For Ministry of Health of Israel [\[74\]](#page-24-8) ("Israel") (see also Reicher et al. [\[99\]](#page-27-5)), mortality data obtained from [https://en.wikipedia.org/wiki/COVID-19_pandemic_](https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Israel) [in_Israel](https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Israel) (accessed July 27, 2021) which references Israel's Ministry of Health' official coronavirus updates, it's Telegram channel, and Israel's Corona National Information and Knowledge Center. Data for the proportion aged over 65 is from [https://brookdale.jdc.org.il/wp-content/uploads/2018/02/MJB-Facts_](https://brookdale.jdc.org.il/wp-content/uploads/2018/02/MJB-Facts_and_Figures_Elderly-65_in_Israel-2018_English.pdf) [and_Figures_Elderly-65_in_Israel-2018_English.pdf](https://brookdale.jdc.org.il/wp-content/uploads/2018/02/MJB-Facts_and_Figures_Elderly-65_in_Israel-2018_English.pdf) (accessed July 27, 2021) and GDP value is from OECD. Population for Israel is from World Bank's World Development Indicators (WDI) data. Note that while [\[6\]](#page-17-0) categorizes the sampling method of the Ministry of Health of Israel [\[74\]](#page-24-8) study as "stratified probability," Reicher et al. [\[99\]](#page-27-5) note that the study used blood samples from "insured individuals who arrived at the HMOs [Health Maintenance Organizations] to undergo a blood test for any reason" and caution that, as a consequence, the "study might not reliably represent the entire population."

- For Murhekar et al. [\[79\]](#page-25-3) ("India"), we obtained the number of cumulative deaths for India, from the Our World in Data COVID-19 dataset available at: [ourworldindata.](ourworldindata.org/coronavirus/country/india) [org/coronavirus/country/india](ourworldindata.org/coronavirus/country/india) (accessed on April 28, 2021). We multiplied the number recorded for 14 days after the end of the sampling window of 12,573 by a factor of 3.64 (based on the upper bound of Purkayastha et al. [\[95\]](#page-26-3)'s estimated underreporting factor for India (first wave)) in order to account for potential underreporting. As such, our interval is relatively wide and reflects the uncertainty in the true number of deaths: [4172, 45766]. (Purkayastha et al. [\[95\]](#page-26-3): "Estimates from epidemiological models: For wave 1 our estimate ... [is] an underreporting factor for cases estimated at 11.11 (95% CrI 10.71 – 11.47) and for deaths at 3.56 (95% CrI 3.48 – 3.64).") Data for the proportion aged over 65 is from World Bank's World Development Indicators (WDI) data (see [https:](https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS) [//data.worldbank.org/indicator/SP.POP.65UP.TO.ZS](https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS) (last updated 2021-03-19)). GDP value is from OECD database. Population value is from the World Bank (see [https:](https://data.worldbank.org/indicator/SP.POP.TOTL?locations=IN) [//data.worldbank.org/indicator/SP.POP.TOTL?locations=IN](https://data.worldbank.org/indicator/SP.POP.TOTL?locations=IN); accessed on April 28, 2021).
- For Nawa et al. [\[82\]](#page-25-8) ("Utsunomiya City, Japan"), we concluded that 0 deaths had occurred based on official records for the Tochigi prefecture (see [https://www.nippon.com/](https://www.nippon.com/en/japan-data/h00657/) [en/japan-data/h00657/](https://www.nippon.com/en/japan-data/h00657/); accessed July 12th, 2021). Data for proportion aged over 65 is from [https://www8.cao.go.jp/kourei/english/annualreport/2017/pdf/c1-1.](https://www8.cao.go.jp/kourei/english/annualreport/2017/pdf/c1-1.pdf) [pdf](https://www8.cao.go.jp/kourei/english/annualreport/2017/pdf/c1-1.pdf) (accessed July 12th, 2021). GDP value is from OECD database for Northern-Kanto, Koshin (JPC) region. Population value is from [https://www.city.utsunomiya.](https://www.city.utsunomiya.tochigi.jp/shisei/gaiyo/1007461.html) [tochigi.jp/shisei/gaiyo/1007461.html](https://www.city.utsunomiya.tochigi.jp/shisei/gaiyo/1007461.html) (accessed July 12th).
- For Office of National Statistics [\[85\]](#page-25-5) ("England, UK (1)"), we obtained the number of cumulative deaths for England from the UK coronavirus dashboard ([https://coronavirus.](https://coronavirus.data.gov.uk/details/deaths?areaType=nation&areaName=England) [data.gov.uk/details/deaths?areaType=nation&areaName=England](https://coronavirus.data.gov.uk/details/deaths?areaType=nation&areaName=England); accessed on April 29, 2021). Seroprevalence numbers were obtained from Table 3a of [https://www.](https://www.ons.gov.uk/file?uri=/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2020/previous/v26/covid19infectionsurveydatasets20201002.xlsx) [ons.gov.uk/file?uri=/peoplepopulationandcommunity/healthandsocialcare/](https://www.ons.gov.uk/file?uri=/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2020/previous/v26/covid19infectionsurveydatasets20201002.xlsx) [conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/](https://www.ons.gov.uk/file?uri=/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2020/previous/v26/covid19infectionsurveydatasets20201002.xlsx) [2020/previous/v26/covid19infectionsurveydatasets20201002.xlsx](https://www.ons.gov.uk/file?uri=/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2020/previous/v26/covid19infectionsurveydatasets20201002.xlsx) ; (accessed on April 28, 2021). Data for the proportion aged over 65 is for England from 2019 as listed by LG Inform (see <https://tinyurl.com/4vhrb2uu>; accessed on April 29, 2021). GDP value is obtained by taking the average of values listed in the OECD database for the regions of "South West England", "North East England", "East of England", "North West England", and "South East England". Population value is from the Office of National Statistics report: "Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2020"' (see Table 2) ([https:](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2020)

[//www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2020) [populationestimates/bulletins/annualmidyearpopulationestimates/](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2020) [mid2020](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2020); accessed July 30, 2021).

- For Pagani et al. [\[86\]](#page-25-9) ("Castiglione d'Adda, Italy"), data was taken directly from the paper. For instance, Pagani et al. [\[86\]](#page-25-9) does not cite a specific source for deaths but notes: "From the 1st of January to the 31st of March 2020, 76 deaths (1.65% of the population) have been recorded in CdA, of which 47 were officially attributed to COVID-19." We have not been able to verify these numbers using a publically available dataset. For population, Pagani et al. [\[86\]](#page-25-9) states that "Castiglione d'Adda (CdA) is a town of 4605 inhabitants (according to data from the local registry office at the time of our study) [...]". Data for the proportion aged over 65 is from [https://www.citypopulation.de/en/italy/localities/](https://www.citypopulation.de/en/italy/localities/lombardia/lodi/09801410001__castiglione_dadda/) [lombardia/lodi/09801410001__castiglione_dadda/](https://www.citypopulation.de/en/italy/localities/lombardia/lodi/09801410001__castiglione_dadda/) (accessed July 27, 2021). GDP value is from OECD database for Lombardy region (ITC4).
- For Petersen et al. [\[90\]](#page-26-0) ("Faroe Islands, Denmark"), information on deaths for the Faroe Islands was obtained from <corona.fo/hagtol>, the government information website concerning COVID19 in the Faroe Islands. GDP value is from value listed for Denmark from OECD database. Data for the proportion aged over 65 is from Index mundi (see <https://tinyurl.com/bb2pwrx6>; accessed on April 29, 2021) which cites the CIA World Factbook as a source. Population value is from Petersen et al. [\[90\]](#page-26-0) ("In the Faroe Islands, a geographic isolate of 52,154 inhabitants.").
- For Pollan et al. [\[92\]](#page-26-8) ("Spain"), data for the number of deaths was obtained from Wikipedia (en.wikipedia.org/wiki/COVID-19_pandemic_in_Spain; accessed on April 28, 2021) which sourced the information from the Centro Nacional de Epidemiología (<cnecovid.isciii.es/covid19/>). Note that, the number of deaths of for 2020-05-11 of 26,920 (14 days after the start of the sampling window), is actually higher than the number of deaths for 2020-05-25 of 26,834 (14 days after the end of the sampling window). This may be due to a reporting issue which is noted by Wikipedia: "Figures for 2020-05-24 to 2020-06- 17 include corrections in the validation of past data from several autonomous communities as a result of the transition to a new surveillance methodology implemented from 2020-05- 11." We define the interval as ranging from the lowest value to the highest value, [26,834, 26,920], as listed in Table [5.](#page-58-0) GDP value is from value listed for Spain from OECD database. Data for the proportion aged over 65 is from World Bank's World Development Indicators (WDI) data (see <https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS> (last updated 2021-03-19)). Population value is from the World Bank for 2020 ([https:](https://data.worldbank.org/indicator/SP.POP.TOTL?locations=ES) [//data.worldbank.org/indicator/SP.POP.TOTL?locations=ES](https://data.worldbank.org/indicator/SP.POP.TOTL?locations=ES); accessed July 30, 2021).

- For Radon et al. [\[97\]](#page-27-6) ("Munich, Germany"), the number of deaths was obtained from the official database of the city of Munich (see [https://www.muenchen.de/rathaus/](https://www.muenchen.de/rathaus/Stadtinfos/Coronavirus-Fallzahlen.html) [Stadtinfos/Coronavirus-Fallzahlen.html](https://www.muenchen.de/rathaus/Stadtinfos/Coronavirus-Fallzahlen.html); accessed June 22, 2021). Population data is from [https://web.archive.org/web/20201218195500/https://www.muenchen.](https://web.archive.org/web/20201218195500/https://www.muenchen.de/rathaus/Stadtinfos/Statistik/Bev-lkerung.html) [de/rathaus/Stadtinfos/Statistik/Bev-lkerung.html](https://web.archive.org/web/20201218195500/https://www.muenchen.de/rathaus/Stadtinfos/Statistik/Bev-lkerung.html) (accessed June 22, 2021) and data for those aged over 65 from [https://www.muenchen.de/rathaus/dam/jcr:](https://www.muenchen.de/rathaus/dam/jcr:459cce24-3894-4d4d-b144-4185b750a310/LHM.Stat_Faltkarte_2019_englisch.pdf) [459cce24-3894-4d4d-b144-4185b750a310/LHM.Stat_Faltkarte_2019_englisch.](https://www.muenchen.de/rathaus/dam/jcr:459cce24-3894-4d4d-b144-4185b750a310/LHM.Stat_Faltkarte_2019_englisch.pdf) [pdf](https://www.muenchen.de/rathaus/dam/jcr:459cce24-3894-4d4d-b144-4185b750a310/LHM.Stat_Faltkarte_2019_englisch.pdf) (accessed June 22, 2021). Finally, GDP value is from value listed for Bavaria (GE2) from the OECD database.
- For Reyes-Vega et al. [\[100\]](#page-27-7) ("Lima, Peru"), note that Peru audited death records and their data was updated on May 31, 2021 (see https://www.datosabiertos.gob.pe/dataset/fallecidospor-covid-19-ministerio-de-salud-minsa); see Dyer [\[30\]](#page-20-10). we used official (post-audit) numbers from the Peru Ministry of Health (MINSA) (see [https://www.datosabiertos.](https://www.datosabiertos.gob.pe/dataset/fallecidos-por-covid-19-ministerio-de-salud-minsa/resource/4b7636f3-5f0c-4404-8526) [gob.pe/dataset/fallecidos-por-covid-19-ministerio-de-salud-minsa/](https://www.datosabiertos.gob.pe/dataset/fallecidos-por-covid-19-ministerio-de-salud-minsa/resource/4b7636f3-5f0c-4404-8526) [resource/4b7636f3-5f0c-4404-8526](https://www.datosabiertos.gob.pe/dataset/fallecidos-por-covid-19-ministerio-de-salud-minsa/resource/4b7636f3-5f0c-4404-8526)) for mortality numbers. Note that the target population is Lima Metropolitana, an area that includes both area that includes Peruvian provinces of Lima and Callao. As such, we sum deaths recorded for both Lima and Callao provinces. In order to acknowledge that there is substantial uncertainty in the post-audit mortality numbers, we widened the interval by lowering the lower bound by 10% and increasing the upper bound by 10%. GDP value is from value listed for Lima (PE15) from the OECD database. Data for the population aged over 65 from https://www.citypopulation.de/en/peru/admin/15__lima/ (accessed July 27, 2021). Population value obtained from [https://www.minsa.gob.pe/reunis/data/](https://www.minsa.gob.pe/reunis/data/poblacion_estimada.asp) [poblacion_estimada.asp](https://www.minsa.gob.pe/reunis/data/poblacion_estimada.asp) (accessed July 27, 2021). Note that Reyes-Vega et al. [\[100\]](#page-27-7) state that: "The study area has an estimated 10.7 million inhabitants."
- For Richard et al. [\[101\]](#page-27-1) ("Geneva, Switzerland (2)"), note that this study is excluded from the Chen et al.-based analysis set but included in the Serotracker-based analysis set. For Richard et al. [\[101\]](#page-27-1), mortality data for the canton of Geneva were obtained from an excel file made publicly available by a Swiss government website at: <ge.ch/document/covid-19-donnees-completes-debut-pandemie> (accessed on April 28, 2021). Data for the population and the proportion aged over 65 is from [https://www.bfs.admin.ch/bfs/en/home/statistics/regional-statistics/](https://www.bfs.admin.ch/bfs/en/home/statistics/regional-statistics/regional-portraits-key-figures/cantons/geneva.html) [regional-portraits-key-figures/cantons/geneva.html](https://www.bfs.admin.ch/bfs/en/home/statistics/regional-statistics/regional-portraits-key-figures/cantons/geneva.html) (accessed on April 28, 2021). GDP value is from value listed for Lake Geneva Region (CH01) from the OECD database.

- For Samore et al. [\[105\]](#page-27-8) ("Four counties in UT, USA"), data for the number of deaths for the counties of Utah county, Salt Lake county, Davis county, and Summit county, was obtained from the county-level COVID-19 dataset curated by the New York Times available at: <github.com/nytimes/covid-19-data> (accessed on April 28, 2021). Data for the proportion aged over 65 is from [https://github.com/JieYingWu/COVID-19_](https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/blob/master/data/README.md) [US_County-level_Summaries/blob/master/data/README.md](https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/blob/master/data/README.md) (accessed on April 29, 2021). GDP value is from value listed for the state of Utah, USA (US49) in the OECD database. Population value is from US county-level census data for 2019 for the four counties (636235+1160437+355481+42145) (see [https://www.census.gov/data/](https://www.census.gov/data/datasets/time-series/demo/popest/2010s-counties-total.html) [datasets/time-series/demo/popest/2010s-counties-total.html](https://www.census.gov/data/datasets/time-series/demo/popest/2010s-counties-total.html); accessed July 30, 2021).
- For Santos-Hövener et al. [\[106\]](#page-28-6) ("Kupferzell, Germany"), data for the number of deaths for Kupferzell, Germany was obtained directly from Santos-Hövener et al. [\[106\]](#page-28-6) which cites the Robert Koch Institute. Despite efforts, no publicly available dataset was found which could confirm these numbers specific these numbers. Data for the proportion aged over 65 is from: [https://ugeo.urbistat.com/AdminStat/en/de/demografia/eta/](https://ugeo.urbistat.com/AdminStat/en/de/demografia/eta/kupferzell/20172564/4) [kupferzell/20172564/4](https://ugeo.urbistat.com/AdminStat/en/de/demografia/eta/kupferzell/20172564/4) (accessed on April 29, 2021). GDP value is from value listed for Baden-Württemberg (DE1) from the OECD database. Population value is from Wikipedia (<https://als.wikipedia.org/wiki/Kupferzell>; accessed July 30, 2021) which cites the Statistisches Landesamt Baden-Württemberg – Bevölkerung nach Nationalität und Geschlecht am 31. Dezember 2019 (CSV-Datei).
- For Selvaraju et al. [\[107\]](#page-28-7) ("Chennai, Tamil Nadu, India"), mortality data for the number of deaths for Chennai were obtained from the Greater Chennai Corporation (see <http://covid19.chennaicorporation.gov.in/>; specifically, numbers published for July 15, 2020 and August 14, 2020 were listed at: [https://twitter.com/chennaicorp/](https://twitter.com/chennaicorp/status/1283280173132128259) [status/1283280173132128259](https://twitter.com/chennaicorp/status/1283280173132128259) and [https://twitter.com/chennaicorp/status/](https://twitter.com/chennaicorp/status/1294140456868052993) [1294140456868052993](https://twitter.com/chennaicorp/status/1294140456868052993); accessed June 22, 2021). We multiplied the number recorded for 14 days after the end of the sampling window of 2,384 by a factor of 2.5 (based the upper bound of Mukherjee et al. [\[76\]](#page-24-2)'s estimated underreporting factor for Tamil Nadu) in order to account for potential underreporting. Note that Ariel Karlinsky has assembled excess mortality data for Chennai (see: [https://github.com/akarlinsky/](https://github.com/akarlinsky/world_mortality/tree/main/local_mortality) [world_mortality/tree/main/local_mortality](https://github.com/akarlinsky/world_mortality/tree/main/local_mortality); accessed August 4, 2021). These data, taking into account the weekly numbers and five-year pre-pandemic trend suggest an interval of [1344, 2454]. However, we prefer not to use this much narrower interval since the excess mortality data have not been adjusted to account for the potentially substantial underreporting of all-cause deaths (see discussion in Anand et al.

> [\[4\]](#page-17-6)). Data for the proportion aged over 65 is from: [https://statisticstimes.com/](https://statisticstimes.com/demographics/india/tamil-nadu-population.php) [demographics/india/tamil-nadu-population.php](https://statisticstimes.com/demographics/india/tamil-nadu-population.php) (accessed June 22, 2021). GDP value is from value listed for Tamil Nadu (IN33) from the OECD database. Population value is from <https://www.populationu.com/cities/chennai-population> (accessed June 22, 2021).

- For Sharma et al. [\[110\]](#page-28-8) ("Delhi, India"), infection rate estimates are based on survey data from round 1 of the study (August 1-7). Data for the number of deaths for Delhi was obtained from Wikipedia (en.wikipedia.org/wiki/COVID-19_pandemic_in_Delhi; accessed on April 28, 2021) which sourced the information from the Delhi State Health Bulletin (<https://delhifightscorona.in/>). We multiplied the number recorded for 14 days after the end of the sampling window of 4,270 by a factor of 6.3 (based on Mukherjee et al. [\[76\]](#page-24-2)'s estimated underreporting factor) in order to account for potential underreporting. As such, our interval is relatively wide and reflects the uncertainty in the true number of deaths: [4,188, 26,901]. Data for the proportion aged over 65 is from Statistics Times for 2011 ([http://statisticstimes.com/demographics/india/delhi-population.](http://statisticstimes.com/demographics/india/delhi-population.php) [php](http://statisticstimes.com/demographics/india/delhi-population.php); accessed on April 29, 2021). GDP value is from value listed for the National Capital Territory of Delhi (IN03) from the OECD database. Note that we use 18.9 million as the estimated population of Delhi, the number cited by both Sharma et al. [\[110\]](#page-28-8) and Bhattacharyya et al. [\[17\]](#page-18-9), while Chen et al. [\[28\]](#page-20-1) use a much different number: 30,290,936 (see Table S14 in Supplementary appendix 2 of Chen et al. [\[28\]](#page-20-1)).
- Snoeck et al. [\[115\]](#page-29-5) ("Luxembourg") "recruited a representative sample of the Luxembourgish population" between April 16th and May 5th, and obtained a 95% CI of [1.23%, 2.77%]. Two different 95% CIs, obtained with and without adjustment for age, gender and canton are provided in the paper: $[1.23\%; 2.67\%]$ and $[1.34\%; 2.77\%]$. As such, we record [1.23%; 2.77%] for our IR interval. Data for the number of deaths was obtained from the Our World in Data COVID-19 dataset available at: [ourworldindata.org/coronavirus/](ourworldindata.org/coronavirus/country/luxembourg) [country/luxembourg](ourworldindata.org/coronavirus/country/luxembourg) (accessed on April 28, 2021). GDP value is from value listed for Luxembourg (LU00) from the OECD database. Data for the proportion aged over 65 is from World Bank's World Development Indicators (WDI) data (see [https://data.worldbank.](https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS) [org/indicator/SP.POP.65UP.TO.ZS](https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS) (last updated 2021-03-19)). Population value from World Bank for Luxembourg, 2020 (see [https://data.worldbank.org/indicator/SP.](https://data.worldbank.org/indicator/SP.POP.TOTL?locations=LU) [POP.TOTL?locations=LU](https://data.worldbank.org/indicator/SP.POP.TOTL?locations=LU); accessed July 30, 2021). We note that, while Arora et al. [\[6\]](#page-17-0) categorizes the sampling method for the Snoeck et al. [\[115\]](#page-29-5) study as "stratified probability," Snoeck et al. [\[115\]](#page-29-5) explains that "the sample of participants was enrolled through the use of a non-probabilistic web panel" and caution that "[t]here are pros and cons of using web panels for surveys," specifically that "online surveys may be biased samples because the

respondents are self-selected." Levin et al. [\[60\]](#page-23-0) specifically identify Snoeck et al. [\[115\]](#page-29-5) as an example of a "active recruitment" study.

- For Sood et al. [\[116\]](#page-29-6) ("Los Angeles County, CA, USA"), data for the number of deaths for Los Angeles County, CA was obtained from the government of LA county COVID-19 dashboard ([dashboard.publichealth.lacounty.gov/covid19_](dashboard.publichealth.lacounty.gov/covid19_surveillance_dashboard/) [surveillance_dashboard/](dashboard.publichealth.lacounty.gov/covid19_surveillance_dashboard/); accessed on April 28, 2021). Sood et al. [\[116\]](#page-29-6) notes that "Residents of Los Angeles County, California, within a 15-mile (24 km) radius of the testing site were eligible for participation." Data for the proportion aged over 65 is from [https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/](https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/blob/master/data/README.md) [blob/master/data/README.md](https://github.com/JieYingWu/COVID-19_US_County-level_Summaries/blob/master/data/README.md) (accessed on April 29, 2021). GDP value is from value listed for the state of California, USA, (US06) in the OECD database. Population value is from US county-level census data for 2019 (see [https://www.census.gov/data/](https://www.census.gov/data/datasets/time-series/demo/popest/2010s-counties-total.html) [datasets/time-series/demo/popest/2010s-counties-total.html](https://www.census.gov/data/datasets/time-series/demo/popest/2010s-counties-total.html); accessed July 30, 2021).
- For Statistics Jersey [\[118\]](#page-29-7) ("Jersey, UK (1)"), data for the number of deaths was obtained from the Government of Jersey website ([https://www.gov.je/datasets/](https://www.gov.je/datasets/listopendata?listname=COVID19DeathsClassification) [listopendata?listname=COVID19DeathsClassification](https://www.gov.je/datasets/listopendata?listname=COVID19DeathsClassification); accessed on April 28, 2021) summing both "probable COVID-19" deaths and "laboratory proven" COVID-19 deaths. Data for the proportion aged over 65 is from [https://www.indexmundi.com/](https://www.indexmundi.com/jersey/demographics_profile.html) [jersey/demographics_profile.html](https://www.indexmundi.com/jersey/demographics_profile.html) (accessed on April 29, 2021). GDP value is from value listed for United Kingdom (GBR) in the OECD database. Population value is from Statistics Jersey [\[118\]](#page-29-7).
- For Statistics Jersey [\[119\]](#page-29-8) ("Jersey, UK (2)") data for the number of deaths was obtained from the Government of Jersey website ([https://www.gov.je/datasets/listopendata?](https://www.gov.je/datasets/listopendata?listname=COVID19DeathsClassification) [listname=COVID19DeathsClassification](https://www.gov.je/datasets/listopendata?listname=COVID19DeathsClassification); accessed on April 28, 2021) summing both "probable COVID-19" deaths and "laboratory proven" COVID-19 deaths. Data for the proportion aged over 65 is from [https://www.indexmundi.com/jersey/demographics_](https://www.indexmundi.com/jersey/demographics_profile.html) [profile.html](https://www.indexmundi.com/jersey/demographics_profile.html) (accessed on April 29, 2021). GDP value is from value listed for United Kingdom (GBR) in the OECD database. Population value is from Statistics Jersey [\[119\]](#page-29-8).
- For Streeck et al. [\[121\]](#page-29-0) ("Gangelt, Germany"), the number of deaths for Gangelt, Kreis Heinsberg, Germany, is directly noted in the Streeck et al. [\[121\]](#page-29-0) article. No publicly available dataset was found, however we did find information on the Gangelt municipal bulletin (see <www.gangelt.de/news/226-erster-corona-fall-in-nrw>; accessed on April 28, 2021) and an investigative report (see [https://medwatch.de/2020/11/26/](https://medwatch.de/2020/11/26/die-ungezaehlten-todesfaelle-aus-gangelt/) [die-ungezaehlten-todesfaelle-aus-gangelt/](https://medwatch.de/2020/11/26/die-ungezaehlten-todesfaelle-aus-gangelt/); accessed on May 20, 2021) which suggests that 8 to 10 is a reasonable range. Note that the Streeck et al. [\[121\]](#page-29-0) study used both

> antibody-based and PCR-based testing. Data for the proportion aged over 65 is from Figure S1 of Streeck et al. [\[121\]](#page-29-0). GDP value is from value listed for the North Rhine-Westphalia region (DEA) from the OECD database. Population value is from Streeck et al. [\[121\]](#page-29-0) ("In the German community of Gangelt (12,597 inhabitants, January 1, 2020)").

- For Stringhini et al. [\[122\]](#page-29-1) ("Geneva, Switzerland (1)"), mortality data for the canton of Geneva were obtained from an excel file made publicly available by a Swiss government website at: <ge.ch/document/covid-19-donnees-completes-debut-pandemie> (accessed on April 28, 2021). Data for the proportion aged over 65 is from [https://www.bfs.admin.ch/bfs/en/home/statistics/regional-statistics/](https://www.bfs.admin.ch/bfs/en/home/statistics/regional-statistics/regional-portraits-key-figures/cantons/geneva.html) [regional-portraits-key-figures/cantons/geneva.html](https://www.bfs.admin.ch/bfs/en/home/statistics/regional-statistics/regional-portraits-key-figures/cantons/geneva.html). GDP value is from value listed for Lake Geneva Region (CH01) from the OECD database. Population value is from the Swiss Federal Statistical Office ([https://www.bfs.admin.ch/bfs/en/home/](https://www.bfs.admin.ch/bfs/en/home/statistics/regional-statistics/regional-portraits-key-figures/cantons/geneva.html) [statistics/regional-statistics/regional-portraits-key-figures/cantons/](https://www.bfs.admin.ch/bfs/en/home/statistics/regional-statistics/regional-portraits-key-figures/cantons/geneva.html) [geneva.html](https://www.bfs.admin.ch/bfs/en/home/statistics/regional-statistics/regional-portraits-key-figures/cantons/geneva.html); accessed July 30, 2021).
- For Vos et al. [\[130\]](#page-30-8) ("Netherlands"), mortality data for the Netherlands was obtained from the Our World in Data COVID-19 dataset available at: [ourworldindata.org/coronavirus/](ourworldindata.org/coronavirus/country/netherlands) [country/netherlands](ourworldindata.org/coronavirus/country/netherlands) (accessed on April 28, 2021). GDP value is from value listed for Netherlands (NLD) from teh OECD database. Data for the proportion aged over 65 is also from World Bank's World Development Indicators (WDI) data (see [https:](https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS) [//data.worldbank.org/indicator/SP.POP.65UP.TO.ZS](https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS) (last updated 2021-03-19)). Population value is from the World Bank ([https://data.worldbank.org/indicator/](https://data.worldbank.org/indicator/SP.POP.TOTL?locations=NL) [SP.POP.TOTL?locations=NL](https://data.worldbank.org/indicator/SP.POP.TOTL?locations=NL); accessed July 30, 2021).
- For Ward et al. [\[133\]](#page-31-0) ("England, UK (2)"), infection rate estimates are based on survey data from from the first survey (20 June - 13 July). We obtained the number of cumulative deaths for England, from we obtained the number of cumulative deaths for England from the UK coronavirus dashboard ([https://coronavirus.](https://coronavirus.data.gov.uk/details/deaths?areaType=nation&areaName=England) [data.gov.uk/details/deaths?areaType=nation&areaName=England](https://coronavirus.data.gov.uk/details/deaths?areaType=nation&areaName=England); accessed on April 29, 2021). Data for the proportion aged over 65 is for England from 2019 as listed by LG Inform (see <https://tinyurl.com/4vhrb2uu>; accessed on April 29, 2021). GDP value is obtained by taking the average of values listed in the OECD database for the regions of "South West England", "North East England" "East of England", "North West England" and "South East England". Population value is from the Office of National Statistics report: "Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2020"' (See Table 2) ([https:](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2020) [//www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2020)

> [populationestimates/bulletins/annualmidyearpopulationestimates/](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2020) [mid2020](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2020); accessed July 30, 2021).

• For Yoshiyama et al. [\[137\]](#page-31-5) ("Tokyo, Japan"), for the number of deaths for "2020-06-15" and "2020-06-21", we used official numbers from the Japanese Ministry of Health, Labour, and Welfare (see: <https://www.mhlw.go.jp/content/10906000/000640012.pdf> and <https://www.mhlw.go.jp/content/10906000/000641965.pdf>; accessed August 6, 2021). Data for the population and the proportion of the population aged over 65 is from the Tokyo metropolitan government ([https://www.metro.tokyo.lg.jp/tosei/](https://www.metro.tokyo.lg.jp/tosei/hodohappyo/press/2021/01/28/01.html) [hodohappyo/press/2021/01/28/01.html](https://www.metro.tokyo.lg.jp/tosei/hodohappyo/press/2021/01/28/01.html) and [https://www.metro.tokyo.lg.jp/](https://www.metro.tokyo.lg.jp/ENGLISH/ABOUT/HISTORY/history03.htm) [ENGLISH/ABOUT/HISTORY/history03.htm](https://www.metro.tokyo.lg.jp/ENGLISH/ABOUT/HISTORY/history03.htm); accessed August 6, 2021) and GDP value is obtained by taking the average of values listed in the OECD database for the regions of "Northern-Kanto, Koshin" (JPC) and "Southern-Kanto" (JPD).

7.4 Sensitivity analyses

As a sensitivity analysis, we repeated both analyses with an alternative set of priors. For these alternative analyses, we used: $g^{-1}(\theta_0) \sim Uniform(0,1)$; $g^{-1}(\beta) \sim Uniform(0,1)$; $\theta_1 \sim$ $\mathcal{N}(0, 100)$; $\theta_2 \sim \mathcal{N}(0, 100)$; $\sigma \sim$ half- $\mathcal{N}(0, 100)$ and $\tau \sim$ half- $\mathcal{N}(0, 100)$. The results are plotted in Figures [7](#page-53-0) and [8.](#page-54-0)

We also conducted alternative analyses excluding studies for which the mortality data were not obtained directly from official and reliable sources. See results in Figures [5](#page-51-0) and [6.](#page-52-0) Without the excluded studies, we are unable to provide a reasonable "World" estimate (see the extremely wide credible intervals). However, the "USA" and "EU" estimates are relatively unchanged.

Figure 5: Chen et al.-based analysis results with only those studies for which mortality data was directly (i.e., without any adjustments needed) obtained from official sources known to be reliable. Posterior median estimates for the IR_k and IFR_k variables (for $k = 1, ..., 18$) with 95% HPD CrIs. Studies are listed from top to bottom according to increasing fitted values (these values are indicated by \times). Also plotted, under the labels "World (65 yo=9%, GDP=17.8K)", "USA (65 yo=16%, GDP=65.3K)", "EU (65 yo=20%, GDP=47.8K)", are the posterior median estimate and 95% HPD CrIs for the typical IFR corresponding to values for the proportion of the population aged 65 years and older of 9% and for GDP per capita of \$17,811 (the worldwide values), of 16% and of \$65,298 (the USA values), and of 20% and of \$47,828 (the EU values).

Figure 6: Serotracker-based analysis results with only those studies for which mortality data was directly (i.e., without any adjustments needed) obtained from official sources known to be reliable. Posterior median estimates for the IR_k and IFR_k variables (for $k = 1, ..., 18$) with 95% HPD CrIs. Studies are listed from top to bottom according to increasing fitted values (these values are indicated by \times). Also plotted, under the labels "World (65 yo=9%, GDP=17.8K)", "USA (65 yo=16%, GDP=65.3K)", "EU (65 yo=20%, GDP=47.8K)", are the posterior median estimate and 95% HPD CrIs for the typical IFR corresponding to values for the proportion of the population aged 65 years and older of 9% and for GDP per capita of \$17,811 (the worldwide values), of 16% and of \$65,298 (the USA values), and of 20% and of \$47,828 (the EU values).

Figure 7: Analysis results from the Chen et al.-based analysis with alternative priors: posterior median estimates for the IFR_k variables (for $k = 1, \ldots, 18$) with 95% HPD CrIs. Studies are listed from top to bottom according to increasing fitted values (these values are indicated by \times). Also plotted, under the labels "World (65 yo=9%, GDP=17.8K)", "USA (65 yo=16%, GDP=65.3K)", "EU (65 yo=20%, GDP=47.8K)", are the posterior median estimate and 95% HPD CrIs for the typical IFR corresponding to values for the proportion of the population aged 65 years and older of 9% and for GDP per capita of \$17,811 (the worldwide values), of 16% and of \$65,297 (the USA values), and of 20% and of \$47,828 (the EU values).

Figure 8: Analysis results from the Serotracker-based analysis with alternative priors: posterior median estimates for the IFR_k variables (for $k = 1, \ldots, 18$) with 95% HPD CrIs. Studies are listed from top to bottom according to increasing fitted values (these values are indicated by \times). Also plotted, under the labels "World (65 yo=9%, GDP=17.8K)", "USA (65 yo=16%, GDP=65.3K)", "EU (65 yo=20%, GDP=47.8K)", are the posterior median estimate and 95% HPD CrIs for the typical IFR corresponding to values for the proportion of the population aged 65 years and older of 9% and for GDP per capita of \$17,811 (the worldwide values), of 16% and of \$65,297 (the USA values), and of 20% and of \$47,828 (the EU values).

7.5 MCMC details and R code

Note that, in order to improve the MCMC mixing, we replace the binomial distribution for CC_k as described in [\(2\)](#page-4-0), with

$$
CC_k \sim Binom(T_k, IR_k),\tag{6}
$$

for $k = 1, \ldots, K$. For any sufficiently large P_k , this simplification will make little to no difference. Then, since the distributions of C_k and $D_k|C_k$ are both binomials (see [\(2\)](#page-4-0) and [\(3\)](#page-4-1)), we have that unconditionally:

$$
D_k \sim Binom(P_k, IFR_k \times IR_k). \tag{7}
$$

Note that Z_{1k} was set equal to the centred and scaled logarithm of $65y\mathfrak{o}_k$, and Z_{2k} was set equal to the centred and scaled logarithm of GDP_k .

The following JAGS-code was used in R for the analysis :

```
library("rjags")
metaIFR <- "model {
# Priors:
icloglog_theta0 ~ dbeta(0.3, 30);
icloglog_beta ~ dbeta(1, 3);
theta0 <- log(-log(1-icloglog_theta0));
beta <- log(-log(1-icloglog_beta));
inv.var\_sig <- (1/sigma)^2 ;
inv.var_tau \leq (1/tau)^2 ;
sigma \sim dnorm(0, 1/10) T(0, );
tau \sim dnorm(0, 1/10) T(0, );
theta1 \tilde{ } dnorm(0, 1/10);theta2 \tilde{c} dnorm(0, 1/10);
# Likelihood:
for(k in 1:K){
cc[k] \tilde{d} dbin(ir[k], tests[k]);
    censor.index[k] ~ dinterval(deaths[k], c(deaths_lower[k], deaths_upper[k]))
deaths[k] \tilde{ } dbin(ifr[k]*ir[k], pop[k]);
cloglog(ir[k]) <- cloglog_ir[k];
cloglog(ifr[k]) <- cloglog_ifr[k];
cloglog_ir[k] ~ dnorm(beta, inv.var_sig);
cloglog_ifr[k] \tilde{ } dnorm(theta0 + theta1*Z1[k] + theta2*Z2[k], inv.var_tau);
 }}"
```


Table 2: Seroprevalence studies selected for the analysis based on the list compiled by Chen et al. [\[28\]](#page-20-1) (listed in alphabetical order of authors), with geographic location of sampling, sampling dates, and 95% uncertainty interval for the infection rate (IR interval).

Table 3: Seroprevalence studies selected for the analysis based on the list compiled by Serotracker (listed in alphabetical order of authors), with geographic location of sampling, sampling dates, and 95% uncertainty interval for the infection rate (IR interval).

Table 4: The Chen et al. based dataset required for the Bayesian evidence synthesis model.

Table 5: The Serotracker based dataset required for the Bayesian evidence synthesis model.